SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
[ ] ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
[x] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from September 30, 1995 to December 31, 1995
Commission file number 0-20594
COMPSCRIPT, INC.
----------------------------------------------
(Name of Small Business Issuer in Its Charter)
FLORIDA 65-0506539
- ------------------------------- -------------------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
1225 BROKEN SOUND PARKWAY
BOCA RATON, FLORIDA 33481
--------------------------------------------------
(Address of Principal Executive Offices)(Zip Code)
(407) 994-8585
------------------------------------------------
(Issuer's Telephone Number, Including Area Code)
Securities registered under Section 12(b) of the Securities Exchange Act of
1934:
Name of Each Exchange
TITLE OF EACH CLASS ON WHICH REGISTERED
- ------------------- -------------------
NONE NONE
Securities registered pursuant to Section 12(g) of the Securities Exchange Act
of 1934:
COMMON STOCK, PAR VALUE $.0001 PER SHARE
----------------------------------------
(Title of Class)
CLASS "A" COMMON STOCK PURCHASE WARRANTS
----------------------------------------
(Title of Class)
CLASS "B" COMMON STOCK PURCHASE WARRANTS
----------------------------------------
(Title of Class)
<PAGE>
Check whether the registrant: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [x] No [ ]
Check if disclosure of delinquent filers in response to Item 405 of Regulation
S-B is not contained in this form, and no disclosure will be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. [x]
State registrant's revenues for the three months ended December 31, 1995:
$2,903,723
State the aggregate market value of the voting stock held by non-affiliates of
the registrant on September 30, 1996, computed by reference to the closing bid
price of the Compscript, Inc. Common Stock as reported by THE WALL STREET
JOURNAL on that date: $31,753,712.50
APPLICABLE ONLY TO CORPORATE ISSUERS
------------------------------------
The number of shares outstanding of the registrant's Common Stock, par value
$.01 per share (the "Common Stock"), as of September 30, 1996, was 10,708,913.
DOCUMENTS INCORPORATED BY REFERENCE
-----------------------------------
None.
<PAGE>
PART 1
THE COMPANY
Item 1. DESCRIPTION OF BUSINESS
Information included or incorporated by reference in this Transition Report on
Form 10-KSB, and information that may be contained in other filings by the
Company with the Securities and Exchange Commission and releases issued or
statements made by the Company, contain or may contain forward- looking
statements that involve risks and uncertainties. The Company's actual results
may differ significantly from those projected or suggested in the
forward-looking statements. Factors that might cause such a difference to occur
include, but are not limited to, heightened competition, including specifically
increased price competition in the pharmacy benefit management market; the
termination of the Company's contracts with certain key clients; adverse results
in certain litigation and regulatory matters; and the adoption of adverse
legislation or regulations or a change in the interpretation of existing
legislation or regulations.
COMPANY OVERVIEW
On April 26, 1996, CompScript, Inc. (formerly Capital Brands, Inc.) (the
"Company" or "CompScript") acquired approximately 93% of the outstanding common
stock of CompScript-Boca, Inc. (formerly CompScript, Inc.) ("CompScript-Boca"),
a privately-held provider of pharmacy management services by merger of the
Company into CompScript-Boca in exchange for issuance of 7,394,982 shares of the
Company's common stock. As a result of this transaction, CompScript-Boca
shareholders became the owners of approximately 80% of the Company's then
outstanding common stock and assumed 100% Control of the Company's Board of
Directors. Accordingly, the acquisition has been treated for financial reporting
purposes as a reverse acquisition. After completion of the transaction, the
Company became the owner of approximately 93% of the outstanding common stock of
CompScript-Boca and accordingly, recorded a minority interest in the acquired
subsidiary of $222,628, representing approximately 7% of the net assets of the
acquired subsidiary on the date of acquisition.
The purchase price of the Company by CompScript-Boca of $3,041,836
was comprised of the 1,806,750 shares deemed to have been issued and acquisition
costs. The purchase price was allocated to the estimated fair value of assets
acquired of $2,150,000, and the acquisition costs of $891,836 were charged
against paid in capital since the Company had insignificant operations at the
date of the reverse acquisition.
CompScript, Inc. is a comprehensive provider of pharmacy management services
equipped to both lower costs and improve the quality of care. CompScript offers
a broad range of pharmacy, infusion therapy, consulting services, mail order,
and pharmacy benefit claim administration to managed care networks, long-term
and subacute care facilities, home health patients, and recipients of managed
care. CompScript's proprietary pharmacy management capabilities combine
sophisticated clinical tools with the latest technologies in databases and drug
profiles. CompScript's network of participating retail pharmacies, along with
electronic on-line adjudication system and a mail service dispensing facility,
allow CompScript to offer a fully integrated pharmacy benefit management
program.
CompScript operates two institutional pharmacies that serve long-term and
subacute facilities in Florida, Alabama and Mississippi.
Capital Brands, Inc.'s ("Capital Brands") predecessor, Capital Acquisitions,
Inc. was incorporated in March 1988 as a Delaware corporation. Prior to
September, 1991, Capital Brands was principally engaged in organizational
activities, raising capital through a public offering and searching for and
investigating business opportunities. From 1991 to consummation of the agreement
with the Company, Capital Brands,
3
<PAGE>
through its direct or indirect subsidiaries, was involved in the development and
operation of Burger King Restaurants in the Republic of Poland, the development
and operation of Domino's Pizza Stores in Poland, the development and operation
of centers which provide medically supervised weight loss services in South
Florida, the development and operation of fast food chicken shops in Florida and
the attempted development and operation of Holiday Inn Express Hotels in Poland.
Immediately prior to the share exchange with the Company, Capital Brands, Inc.
divested itself of its interest in all businesses except for its ownership
interest in QPQ Corporation. On July 26, 1996, the Company sold its ownership
interest in QPQ to the former Chairman of the Board and Chief Executive Officer
and President of Capital Brands.
PRODUCTS AND SERVICES
INSTITUTIONAL PHARMACY. CompScript purchases, repackages and dispenses
prescription and non-prescription medication in accordance with physician orders
and delivers such prescriptions at least daily to the nursing facilities for
administration to individual patients by the facility's nursing staff.
CompScript typically services nursing homes within a 150-mile radius of its
pharmacy locations. CompScript maintains a 24- hour, on-call pharmacist service
365 days per year for emergency dispensing and delivery or for consultation with
the facility's staff or attending physician.
Upon receipt of a prescription, the relevant patient information is entered into
CompScript's computerized dispensing and billing systems. At that time, the
dispensing system will check the prescription for any potentially adverse drug
interactions or patient sensitivity. When required and/or specifically requested
by the physician or patient, branded drugs are dispensed; generic drugs are
substituted in accordance with applicable state and federal laws and as
requested by the physician or patient. The Company also provides therapeutic
interchange, with physician approval, in accordance with the company's
pharmaceutical care guidelines.
CompScript provides a "modified unit-dose" distribution system. Most of its
prescriptions are filled utilizing specialized unit-of-use packaging and
delivery systems. Maintenance medications are typically provided in 30-day
supplies utilizing either a box unit-dose system or unit-dose punch card system.
The unitdoses system, preferred over the bulk delivery systems employed by
retail pharmacies, improves control over drugs in the nursing facility and
improves patient compliance with drug therapy by increasing the accuracy and
timeliness of drug administration.
Integral to CompScript's drug distribution system is its computerized medical
records and documentation system. CompScript provides to the facility
computerized medication administration records and physician's order sheets and
treatment records for each patient. Data extracted from these computerized
records are also formulated into monthly management reports on patient care and
quality assurance. The computerized documentation system in combination with the
modified unit-dose drug delivery system results in greater efficiency in nursing
time, improved control, reduced drug waste in the facility and lower error rates
in both dispensing and administration. These benefits improve drug efficacy and
result in fewer drug-related hospitalizations.
CONSULTANT PHARMACIST SERVICES. Federal and state regulations mandate that
nursing facilities, in addition to providing a source of pharmaceuticals, retain
consultant pharmacist services to monitor and report on prescriptions drug
therapy in order to maintain and improve the quality of patient care. The
Omnibus Budget Reconciliation Act ("OBRA") implemented in 1990 seeks to further
upgrade and standardize care by setting forth more stringent standards relating
to planning, monitoring and reporting on the progress of prescription drug
therapy as well as facility-wide drug usage.
CompScript provides consultant pharmacist services which help clients comply
with such federal and state regulations applicable to nursing homes. Consultant
pharmacists work on a proprietary laptop program to offer institutions patient
specific clinical data. The services offered by CompScript's consultant
pharmacists include: (i) comprehensive, monthly drug regimen reviews for each
patient in the facility to assess the
4
<PAGE>
appropriateness and efficacy of drug therapies, including a review of the
patient's medical records, monitoring drug reactions to other drugs or food,
monitoring lab results and recommending alternate therapies or discontinuing
unnecessary drugs; (ii) participation on the Pharmacy and Therapeutics, Quality
Assurance and other committees of client nursing facilities as well as periodic
involvement in staff meetings; (iii) monthly inspection of medication carts and
storage rooms; (iv) monitoring and monthly reporting on facility-wide drug usage
and drug administration systems and practices; (v) development and maintenance
of pharmaceutical policy and procedures manuals; and (vi) assistance to the
nursing facility in complying with state and federal regulations as they pertain
to patient care.
Additionally, CompScript offers a specialized line of consulting services which
help nursing facilities to enhance care and reduce and contain costs as well as
to comply with state and federal regulations. Under this service line,
CompScript provides: (i) data required for OBRA and other regulatory purposes,
including reports on psychotropic drug usage (chemical restraints), antibiotic
usage (infection control) and other drug usage; (ii) Plan of Care programs which
assess each patient's state of health upon admission and monitor progress and
outcomes using data on drug usage as well as dietary, physical therapy and
social service inputs; (iii) counseling related to appropriate drug usage and
implementation of drug protocols; (iv) on-site educational seminars for the
nursing facility staff on topics such as drug information relating to clinical
indications, adverse drug reactions, drug protocols and special geriatric
considerations in drug therapy, and information and training on intravenous drug
therapy and updates on OBRA and other regulatory compliance issues; (v) mock
regulatory reviews for nursing staffs; and (vi) nurse consultant services and
consulting for dietary, social services and medical records.
ANCILLARY SERVICES. CompScript provides the following ancillary products and
services to nursing facilities:
Infusion Therapy Products and Services. With cost containment pressures in the
health care industry, nursing facilities are increasingly providing subacute
care as a means of treating moderately acute but stabilized patients more
cost-effectively than hospitals, provided that the nursing staff and pharmacy
are capable of supporting higher degrees of acuity. CompScript provides infusion
therapy support services for such residents in its client nursing facilities
and, to a lesser extent, hospice and home care patients. Infusion therapy
consists of the product (a nutrient, antibiotic, chemotherapy or other drugs in
solution) and the intravenous ("IV") administration of the product.
CompScript prepares the product to be administered using proper equipment in a
sterile environment and then delivers the product to the nursing home for
administration by the nursing staff. Proper administration of IV drug therapy
requires a highly trained nursing staff. CompScript's consultant pharmacists and
nurse consultants operate an education and certification program on IV therapy
to assure proper staff training and compliance with regulatory requirements in
client facilities offering an IV program.
By providing an infusion therapy program, CompScript enables its client nursing
facilities to admit and retain patients who otherwise would need to be cared for
in an acute-care facility. CompScript's proprietary computer system and
specialization in the subacute arena have been instrumental in new business
development and the reason over 65% of the facilities are considered subacute or
competent in IV therapy. The Company believes that by providing these high
acuity pharmacy services it has a competitive advantage over other pharmacy
providers. The most common infusion therapies CompScript provides in the nursing
home environment are total parenteral nutrition, antibiotic therapy,
chemotherapy, pain management and hydration.
HOME INFUSION THERAPY SERVICES. CompScript has established a Joint Commission on
Accreditation of Healthcare Organizations ("JCAHO") accredited home infusion
company to serve homebound patients. CompScript offers outcomes management with
an emphasis on diagnosis of level of severity, specialized management reporting,
and statewide coverage, which makes CompScript particularly attractive to
managed care companies. CompScript offers managed care companies a full
continuum of coverage for their clients, from hospitals to subacute units to
long-term care ("LTC") facilities to the patients' homes.
5
<PAGE>
Infusion therapy services involve the administration of prescription drugs and
other products that are prescribed by a physician to a patient by catheter,
feeding tube or intravenously. The Company's managed care clients benefit from
outpatient infusion therapy services because the length of hospital stays can be
reduced. Rather than receiving infusion therapy in a hospital, the Company can
provide infusion therapy services to patients at home, in a physician's office
or in a free-standing center operated by a health maintenance organization
("HMO") or other entity. The Company provides antimicrobial, cardiovascular,
hematologic, nutritional, pain management, chemotherapeutic, hydration,
endocrine, respiratory and AIDS management treatments to patients.
PHARMACY BENEFIT MANAGEMENT SERVICES. The Company's pharmacy benefit management
("PBM") service is the systematic management of outpatient prescription drug
usage to foster high quality, cost-effective pharmaceutical care through the
application of managed care principles and development of information
technologies. PBM services consist of retail pharmacy network administration,
except in the Long-Term Care Pharmacy Network; formulary administration;
electronic point-of-sale claims processing, drug utilization review ("DUR");
mail pharmacy service; and benefit plan design consultation. Advanced PBM
services include the development of advanced formulary compliance and
therapeutic substitution programs; therapy management services such as prior
authorization, therapy guidelines, step therapy protocols, and disease
management interventions, and sophisticated management information reporting and
analytic services.
The Company contracts with retail pharmacies to provide prescription drugs to
members of the pharmacy benefit plans managed by the Company. These pharmacies
typically discount the price at which they will provide drugs to members in
return for designation as a network pharmacy. The Company manages three national
networks that are responsive to various client needs related to cost containment
and convenience of access for members.
The Company is a provider of PBM services to the managed care industry,
including several large U.S. HMOs. Some of the Company's largest managed care
clients include Health Plan of Florida ("HIP"), and Inphynet Medical Management
Inc.
LONG-TERM CARE PHARMACY NETWORK. In May of 1995, CompScript believes that it
formed the first of its kind, Long-Term Care Pharmacy Network. The network is
comprised of long-term care "closed-shop" institutional pharmacies. This network
is organized to provide full comprehensive services to the institutionalized
frail elderly population with the consistencies of one long-term care model
benefit. This network is being marketed to payers with both national and
regional interests as one pharmaceutical vendor for their long-term/chronic care
pharmaceutical care beneficiaries.
GROUP HEALTHCARE AND WORKERS' COMPENSATION NETWORKS. The Company uses on-line
electronic claims processing to provide effective pharmacy benefit management
services to its clients. All retail pharmacies in the Company's pharmacy network
communicate with the Company on-line and in real time to process prescription
drug claims. When a member of a plan presents his or her identification card at
a network pharmacy, the network pharmacist sends the specified claim data in an
industry standard format to the Company which processes the claim and responds
to the pharmacy, typically within a few seconds. The electronic processing of
the claim involves confirming the member's eligibility for benefits under the
applicable health benefit plan and the conditions to or limitations of coverage,
such as the amount of copayments or deductibles the member must pay; performing
a concurrent DUR analysis and alerting the pharmacist to possible drug
interactions or other indications of inappropriate prescription drug usage;
updating the member's prescription drug claim record; and, if the claim is
accepted, confirming to the pharmacy that it will receive payment for the drug
dispensed.
The Company provides advanced PBM services to its clients which involve the
application of clinical expertise and sophisticated management information
systems to manage the pharmacy benefit. An important advanced PBM service
provided by the Company is the enhancement of formulary compliance. Formularies
6
<PAGE>
are lists of drugs for which coverage is provided under the applicable plan;
they are widely used in managed health care plans and, increasingly, by other
healthcare risk managers. The Company administers a number of different
formularies for its clients that often identify preferred drugs whose use is
encouraged or required through various benefit design features. Historically,
many clients have selected a plan design which includes an open formulary in
which all drugs are covered by the plan and preferred drugs, if any, are merely
recommended. More advanced formularies consist of restricted formularies, in
which various financial or other disincentives exist to the selection of
non-preferred drugs, or closed formularies, in which benefits are available only
for drugs listed on the formulary. Formulary preferences can be encouraged by
restricting the formulary through plan design features such as tiered
copayments, which require the member to pay a higher amount for a nonpreferred
drug; through prescriber education programs, in which the Company or the managed
care client actively seek to educate the prescribers about the formulary
preferences; and through the Company's therapeutic substitution programs that
target certain high-cost therapy classes for concentrated formulary compliance
efforts.
The Company's electronic claims processing system also enables it to implement
sophisticated intervention programs to assist in managing prescription drug
utilization. The system can be used to alert the pharmacist to generic and
therapeutic substitution opportunities and formulary compliance issues, or to
administer prior authorization and therapy protocol programs at the time a claim
is submitted for processing. The Company's claims processing system also creates
a database of drug utilization information that can be accessed on a
retrospective basis to analyze utilization trends and prescribing patterns for
more intensive management of the drug benefit.
The Company is developing disease management programs to assist health plans in
managing the total health care costs associated with certain diseases, such as
diabetes and asthma, for which pharmaceutical therapy is a principal treatment
regimen. A disease management program may entail mailing information about the
disease to health plan members who have the disease. Additionally, the program
includes periodic reminders to encourage compliance with the therapy. High risk
or noncompliant members can be identified and contacted for individual
counseling, and physicians can be encouraged to follow the health plan's
specified therapy protocol for treating the disease. Disease management programs
that promote compliance with the drug regimen can both reduce complications from
the underlying disease and manage the severity of the disease so that more
expensive drugs or medical procedures can be avoided, thus helping to manage the
total health care cost of the disease.
MAIL SERVICE PHARMACY BENEFITS. The Company integrates its pharmacy network
benefits with its mail service pharmacy benefits provided to its clients. It
operates one mail service pharmacy in Florida that provides members with
convenient access to maintenance medications, and enables the Company and its
clients to control drug costs through purchasing efficiencies and other
economies of scale. In addition, through its mail service pharmacy, the Company
is able to be directly involved with the prescriber and member, and is generally
able to achieve a higher level of generic and therapeutic substitution than can
be achieved through the retail pharmacy network, which further reduces the
client's costs.
SUPPLIERS
The Company's inventory in its pharmacies includes over 3,000 brand and generic
pharmaceuticals. If a pharmaceutical is not in its inventory, the Company can
generally obtain it from a supplier within one to two business days. The Company
purchases its pharmaceuticals. Generic pharmaceuticals are generally purchased
directly from manufacturers. The Company believes that alternative sources of
supply for both generic and brand name pharmaceuticals are readily available.
COMPETITION
The Long Term-Care industry is highly fragmented but experiencing significant
consolidation. There are a large number of small companies offering long-term
care pharmacy services. Most of these are smaller
7
<PAGE>
than the Company. By its nature, the long-term care pharmacy business is highly
regionalized and, within a given geographic region of operations, highly
competitive. In the geographic regions it serves, CompScript competes with
numerous local retail pharmacies, local and regional institutional pharmacies
and pharmacies owned by long-term care facilities. CompScript competes in this
market on the basis of quality, cost-effectiveness and the increasingly
comprehensive and specialized nature of its services along with the clinical
expertise, pharmaceutical technology and professional support it offers.
In its program of acquiring institutional pharmacy providers, the Company
competes with several other companies with similar acquisition strategies, some
of which have greater resources than the Company.
No individual customer or market group is critical to the total sales of the
Company's long-term care pharmacy business.
The Company believes that the primary competitive factors in each of its
businesses are price, quality of service and breadth of available services.
CompScript also believes that its larger competitors offer limited core pharmacy
management services that lack the depth and breadth of diversification offered
by the Company, and that most of the Company's smaller competitors offer even
more limited services with greater financial limitations. The Company considers
its principal competitive advantages to be independence from nursing home
owner/operators and drug manufacturers strong managed care knowledge and
experience which supports the development of advanced services, and its
commitment to providing flexible and distinctive service to its customers.
There are a large number of companies offering PBM services in the U.S. Most of
these companies are smaller than the Company and offer their services on a local
or regional basis. As a full service, national pharmacy benefit manager, the
Company competes with a number of larger, national companies, including Medco
Containment Services, Inc., (a subsidiary of Merck & Co., Inc.), Caremark
International, Inc., PCS, Inc. (a subsidiary of Eli Lilly & Company), Value
Health, Inc., Diversified Pharmaceutical Services, Inc. (a subsidiary of Smith
Kline Beecham), and National Prescription Administrators, Inc., as well as
numerous insurance and Blue Cross/Blue Shield plans, certain HMOs and retail
drug chains which have their own pharmacy benefit management capabilities. Many
of these larger companies have greater financial and marketing resources than
the Company.
Consolidation is a critical factor in the pharmaceutical industry generally.
Horizontal and vertical merger and acquisition activity in the manufacturing
segment has been robust, with significant resultant movements in market share.
Competitors that are owned by nursing home owners/operators and manufacturers
may have pricing advantages that are unavailable to the Company and other
independent companies.
With respect to infusion therapy services, the Company competes with a number of
large national companies.
GOVERNMENT REGULATION
LTC PHARMACY
Institutional pharmacies, as well as the long-term care facilities they serve,
are subject to extensive federal, state and local regulation. These regulations
cover required qualifications, day-to-day operations, reimbursement and the
documentation of activities. CompScript continuously monitors the effects of
regulatory activity on its operations.
LICENSURE, CERTIFICATION AND REGULATION. States generally require that companies
operating a pharmacy within the state be licensed by the state board of
pharmacy. The Company currently has pharmacy licenses in each state in which it
operates a pharmacy. In addition, the Company currently delivers prescription
products from one of its licensed pharmacies to one state in which the Company
does not operate a
8
<PAGE>
pharmacy. This state regulates out-of-state pharmacies; however, as a condition
to the delivery of prescription products to patients in this state. CompScript's
pharmacy holds the requisite license applicable for this state. In addition,
CompScript's pharmacies are registered with the appropriate state and federal
authorities pursuant to statutes governing the regulation of controlled
substances.
Client nursing facilities are also separately required to be licensed in the
states in which they operate and, if servicing Medicare or Medicaid patients,
must be certified to be in compliance with applicable program participation
requirements. Client nursing facilities are also subject to the nursing home
reforms of the Omnibus Budget Reconciliation Act of 1987, which imposed strict
compliance standards relating to quality of care for nursing home operations,
including vastly increased documentation and reporting requirements. In
addition, pharmacists, nurses and other health care professionals who provide
services on the Company's behalf are, in most cases, required to obtain and
maintain professional licenses and are subject to state regulations regarding
professional standards of conduct.
MEDICARE AND MEDICAID. The nursing home pharmacy business has long operated
under regulatory and cost containment pressures from state and federal
legislation primarily affecting Medicaid and, to a lesser extent, Medicare.
As is the case for nursing home services generally, CompScript receives
reimbursement from the Medicaid programs, directly from individual residents
(private pay), and from other payors such as third-party insurers. The Company
believes that its reimbursement mix is in line with nursing home expenditures
nationally. For the year ended December 31, 1995, CompScript's payor mix was
approximately as follows: 53% private pay and nursing homes, 42% Medicaid, 4%
Medicare and 1% insurance and other private sources.
For those patients who are not covered by government-sponsored programs or
private insurance, CompScript generally directly bills the patient or the
patient's responsible party on a monthly basis. Depending upon local market
practices, CompScript may alternatively bill private patients through the
nursing facility. Pricing for private pay patients is based on prevailing
regional market rates or "usual and customary" charges.
The Medicaid program is a cooperative federal-state program designed to enable
states to provide medical assistance to aged, blind, or disabled individuals, or
members of families with dependent children whose income and resources are
insufficient to meet the costs of necessary medical services. State
participation in the Medicaid program is voluntary. To become eligible to
receive federal funds, a state must submit a Medicaid "state plan" to the
Secretary of the Department of Health and Human Services ("HHS") for approval.
The federal Medicaid statute specifies a variety of requirements which the state
plan must meet, including requirements relating to eligibility, coverage of
services, payment and administration.
Federal law and regulations contain a variety of requirements relating to the
furnishing of prescription drugs under Medicaid. First, states are given broad
authority, subject to certain standards, to limit or specify conditions to the
coverage of particular drugs. Second, federal Medicaid law establishes standards
affecting pharmacy practice. These standards include general requirements
relating to patient counseling and drug utilization review and more specific
requirements for nursing facilities relating to drug regiment reviews for
Medicaid patients in such facilities. Recent regulations clarify that, under
federal law, a pharmacy is not required to meet the general standards for drugs
dispensed to nursing facility residents if the nursing facility complies with
the drug regimen review requirements. However, the regulations indicate that
states may nevertheless require pharmacies to comply with the general standards,
regardless of whether the nursing facility satisfies the drug regimen review
requirement, and the states in which the Company operates currently do require
its pharmacies to comply therewith.
Second, federal regulations impose certain requirements relating to
reimbursement for prescription drugs furnished to Medicaid patients. In addition
to requirements imposed by federal law, states have substantial
9
<PAGE>
discretion to determine administrative, coverage, eligibility and payment
policies under their state Medicaid programs which may affect the Company's
operations. For example, some states have enacted "freedom of choice"
requirements which may prohibit a nursing facility from requiring its residents
to purchase pharmacy or other ancillary medical services or supplies from
particular providers that deal with the nursing home. Such limitations may
increase the competition which the Company faces in providing services to
nursing facility patients.
The Medicare program is a federally funded and administered health insurance
program for individuals age 65 and over or who are disabled. The Medicare
program consists of two parts: Part A, which covers, among other things,
inpatient hospital, skilled nursing facility, home health care and certain other
types of health care services; and Medicare Part B, which covers physicians'
services, outpatient services, and certain items and services provided by
medical suppliers. Medicare Part B also covers a limited number of specifically
designated prescription drugs. The Medicare program establishes certain
requirements for participation of providers and suppliers in the Medicare
program. Pharmacies are not subject to such certification requirements. Skilled
nursing facilities and suppliers of medical equipment and supplies, however, are
subject to specified standards. Failure to comply with these requirements and
standards may adversely affect an entity's ability to participate in the
Medicare program and receive reimbursement for services provided to Medicare
beneficiaries.
The Medicare and Medicaid programs are subject to statutory and regulatory
changes, retroactive and prospective rate adjustments, administrative rulings,
and freezes and funding reductions, all of which may adversely affect the
Company's business. There can be no assurance that payments for pharmaceutical
supplies and services under governmental reimbursement programs will continue to
be based on the current methodology or remain comparable to present levels. In
this regard, the Company may be subject to rate reductions as a result of
federal budgetary legislation related to the Medicare and Medicaid programs. In
addition, various state Medicaid programs periodically experience budgetary
shortfalls which may result in Medicaid payment delays to the Company. To date,
the Company has not experienced any material adverse effect due to any such
budgetary shortfall. In addition, the failure, even if inadvertent, of
CompScript and/or its client institutions to comply with applicable
reimbursement regulations could adversely affect CompScript's business.
Additionally, changes in such reimbursement programs or in regulations related
thereto, such as reductions in the allowable reimbursement levels, modifications
in the timing or processing of payments and other changes intended to limit or
decrease the growth of Medicaid and Medicare expenditures, could adversely
affect the Company's business.
REFERRAL RESTRICTIONS. The Company is subject to federal and state laws which
govern financial and other arrangements between health care providers. These
laws include the federal anti-kickback statute, which was originally enacted in
1977 and amended in 1987, and which prohibits, among other things, knowingly and
willfully soliciting, receiving, offering or paying any remuneration directly or
indirectly in return for or to induce the referral of an individual to a person
for the furnishing of any item or service for which payment may be made in whole
or in part under Medicare or Medicaid. Many states have enacted similar statutes
which are not necessarily limited to items and services for which payment is
made by Medicare or Medicaid. Violations of these laws may result in fines,
imprisonment, and exclusion from the Medicare and Medicaid programs or other
state-funded programs. Federal and state court decisions interpreting these
statutes are limited, but have generally construed the statutes to apply if "one
purpose" of remuneration is to induce referrals or other conduct within the
statute.
Federal regulations establish "safe harbors," which give immunity from criminal
or civil penalties to parties in good faith compliance. While the failure to
satisfy all criteria for a safe harbor does not mean that an arrangement
violates the statute, it may subject the arrangement to review by the Office of
Inspector General ("OIG"), which is charged with administering the federal
anti-kickback statute. There are no procedures for obtaining binding
interpretations or advisory opinions from the OIG on the application of the
federal anti-kickback statute to an arrangement or its qualification for a safe
harbor upon which the Company can rely.
10
<PAGE>
The OIG issues "Fraud Alerts" identifying certain questionable arrangements and
practices which it believes may implicate the federal anti-kickback statute. The
OIG has issued a Fraud Alert providing its views on certain joint venture and
contractual arrangements between health care providers. The OIG also issued a
Fraud Alert concerning prescription drug marketing practices that could
potentially violate the federal statute. Pharmaceutical marketing activities may
implicate the federal anti-kickback statute because drugs are often reimbursed
under the Medicaid program. According to the Fraud Alert, examples of practices
that may implicate the statute include certain arrangements under which
remuneration is made to pharmacists to recommend the use of a particular
pharmaceutical product.
In addition, a number of states have recently undertaken enforcement actions
against pharmaceutical manufacturers involving pharmaceutical marketing
programs, including programs containing incentives to pharmacists to dispense
one particular product rather than another. These enforcement actions arose
under state consumer protection laws which generally prohibit false advertising,
deceptive trade practices, and the like.
The Company believes its contractual arrangements with other health care
providers, its pharmaceutical suppliers and its pharmacy practices are in
compliance with these laws. There can be no assurance that such laws will not,
however, be interpreted in the future in a manner inconsistent with the
Company's interpretation and application.
HEALTH CARE REFORM AND FEDERAL BUDGET LEGISLATION. The Clinton administration
and members of Congress have proposed plans to reform the health care system.
Currently, Congress is considering such reforms in the context of federal budget
reconciliation legislation. This legislation could result in significant
reductions in payments to providers under the Medicare program and a complete
restructuring and reduced payments to providers under the Medicare program. With
respect to Medicare, proposals include establishment of a prospective payment
system for Skilled Nursing Facilities ("SNFs"); limits on payments to Medicare
SNFs for certain non-routine services, including, among others, prescription
drugs, diagnostic services, and physical therapy and other rehabilitative
services; requiring consolidated billing by a SNF for all Part A and B claims
for SNF residents; and other limits on reimbursement of costs for Medicare SNF
services. If enacted, there can be no assurance that such proposals could not
have a material effect on the business of CompScript. While budget negotiations
are continuing, the future of any reform proposals in Congress is unknown.
In addition, a number of states have enacted and are considering various health
care reforms, including reforms through Medicaid demonstration projects. Federal
law allows HHS to authorize waivers of federal Medicaid program requirements,
including requirements relating to coverage, free choice of providers and
payment for health care services, in connection with state demonstration
projects that promote Medicaid program objectives. HHS published procedures and
public notice requirements designed to open the waiver approval process to
public comment and to expedite processing. Legal actions have been initiated
challenging the waiver process and the authority of HHS to approve waivers for
broad-based Medicaid managed care programs. The federal budget legislation
restructuring the Medicaid program would effectively eliminate Medicaid managed
care demonstration projects.
Several state Medicaid programs have established mandatory statewide managed
care programs for Medicaid beneficiaries to control costs through negotiated or
capitated rates, as opposed to traditional cost-based reimbursement for Medicaid
services, and propose to use savings achieved through these programs to expand
coverage to those not previously eligible for Medicaid. HHS has approved waivers
for statewide managed care demonstration projects in several states, and are
pending for several other states. These demonstration projects generally exempt
institutionalized care, including nursing facility services, from the programs,
and the Company's operations have not been adversely affected with a managed
care demonstration project in effect. The Company is unable to predict what
impact, if any, future projects might have on the Company's operations. Because
there are currently various reform proposals under consideration at the federal
and state levels, it is uncertain at this time what health care reform
initiatives, if any, will be implemented, or whether
11
<PAGE>
there will be other changes in the administration of governmental health care
programs or interpretations or governmental policies or other changes affecting
the health care system. There can be no assurance that future health care or
budget legislation or other changes will not have an adverse effect on the
business of the Company.
Various aspects of the Company's businesses are governed by federal and state
laws and regulations. Since sanctions may be imposed for violations of these
laws, compliance is a significant operational requirement for the Company. The
Company believes that it is in substantial compliance with all existing legal
requirements material to the operation of its businesses.
REPACKAGING. Federal and state laws impose certain repackaging, labeling, and
package insert requirements on pharmacies that repackage drugs for distribution
beyond the regular practice of dispensing or selling drugs directly to patients
at retail. A drug repackager must register with the Food and Drug Administration
("FDA"). The Company holds all required registrations and licenses, and its
repackaging operations are in compliance with applicable state and federal
requirements.
PHARMACY BENEFITS MANAGEMENT REGULATION: GENERALLY
Certain federal and related state laws and regulations affect aspects of the
Company's pharmacy benefit management business. Among these are the following:
FDA REGULATION. The FDA generally has authority to regulate drug promotional
materials that are disseminated "by or on behalf of" a drug manufacturer. In
October 1995, the FDA held hearings to determine whether and to what extent the
activities of pharmacy benefit management companies should be subject to FDA
regulations. At this hearing, FDA officials expressed concern about the efforts
of pharmacy benefit managers (PBMs) that are owned by drug manufacturers to
engage in therapeutic switching programs and about the criteria used by such
PBMs that govern the inclusion and exclusion of particular drugs in formularies.
Various parties, including the Company, have submitted written comments to the
FDA regarding the basis for FDA regulation of PBM activities. It is the
Company's position that, while the FDA may have jurisdiction to regulate PBMs
that are owned by drug manufacturers, the prescription drug benefit programs
developed and implemented by independent PBMs do not constitute the distribution
of materials that promote particular drugs "on behalf of" any pharmaceutical
manufacturers, and therefore, these programs are not subject o FDA regulation.
The FDA has not published any proposed rules to date on the regulation of PBMs,
and there can be no assurance that the FDA will not seek to regulate certain
aspects of the Company's PBM business.
ANTI-REMUNERATION LAWS. Medicare and Medicaid law prohibits, among other things,
an entity from paying or receiving, subject to certain exceptions and "safe
harbors," any remuneration to induce the referral of Medicare or Medicaid
beneficiaries or the purchase (or the arranging for or recommending of the
purchase) of items or service for which payment may be made under Medicare,
Medicaid, or other federally-funded state health care programs. Several states
also have similar laws which are not limited to services for which Medicare or
Medicaid payment may be made. State laws vary and have been infrequently
interpreted by courts or regulatory agencies. Sanctions for violating these
federal and state anti-remuneration laws may include imprisonment, criminal and
civil fines, and exclusion from participation in the Medicare and Medicaid
programs.
The federal statute has been interpreted broadly by courts, the OIG within the
HHS, and administrative bodies. Because of the federal statute's broad scope,
federal regulations establish certain "safe harbors" from liability. Safe
harbors exist for certain properly reported discounts received from vendors,
certain investment interests, and certain properly disclosed payments made by
vendors to group purchasing organizations. A practice that does not fall within
a safe harbor is not necessarily unlawful, but may be subject to scrutiny and
challenge. In the absence of an applicable exception or safe harbor, a violation
of the statute may occur even if only one purpose of a payment arrangement is to
induce patient referrals or
12
<PAGE>
purchases. Among the practices that have been identified by the OIG as
potentially improper under the statute are certain "product conversion programs"
in which benefits are given by drug manufacturers to pharmacists or physicians
for changing a prescription (or recommending or requesting such a change) from
one drug to another. Such laws have been cited as a partial basis, along with
state consumer protection laws discussed below, for investigations and
multi-state settlements relating to financial incentives provided by drug
manufacturers to retail pharmacies in connection with such programs.
To the Company's knowledge, these anti-remuneration laws have not been applied
to prohibit PBMs from receiving discounts from drug manufacturers in connection
with drug purchasing and formulary management programs, to therapeutic
substitution programs conducted by independent PBMs, or to the contractual
relationships such as those the Company has with certain of its customers. The
Company believes that it is in substantial compliance with the legal
requirements imposed by such laws and regulations, and the Company believes that
there are material differences between drug-switching programs that have been
challenged under these laws and the programs offered by the Company to its
customers. However, there can be no assurance that the Company will not be
subject to scrutiny or challenge under such laws or regulations, or that any
such challenge would not have a material effect upon the Company.
OIG STUDY. The OIG's Work Plan for Fiscal Year 1996 indicates that the OIG
Office of Evaluation and inspections (which is not responsible for
investigations of potential violations of anti-remuneration laws, but which
seeks to improve the effectiveness and efficiency of HHS programs) currently is
conducting a study of PBM arrangements particularly with regard to the concerns
and implications for Medicaid beneficiaries. The Company cannot predict the
outcome of the study or the impact, if any, that such study might have on its
business.
ERISA REGULATIONS. The Employee Retirement Income Security Act of 1974 ("ERISA")
regulates certain aspects of employee pension and health benefit plans,
including self-funded corporate health plans with which the Company has
agreements to provide PBM services. The Company believes that the conduct of its
business is not subject to the fiduciary obligations of ERISA, but there can be
no assurance that the U.S. Department of Labor, which is the agency that
enforces ERISA, would not assert that the fiduciary obligations imposed by the
statute apply to certain aspects of the Company's operations.
Numerous state laws and regulations also affect aspects of the Company's
pharmacy benefit management business. Among these are the following:
CONSUMER PROTECTION LAWS. Most states have consumer protection laws that have
been the basis for investigations and multi-state settlements relating to
financial incentives provided by drug manufacturers to retail pharmacies in
connection with drug switching programs. In addition, pursuant to a settlement
agreement entered into with seventeen states on October 25, 1995, Medco
Containment Services, Inc. ("Medco"), the PBM subsidiary of pharmaceutical
manufacturer Merck & Co., agreed to have pharmacists affiliated with Medco mail
service pharmacies disclose to physicians and patients the financial
relationships between Merck, Medco, and the mail service pharmacy when such
pharmacists contact physicians seeking to change a prescription from one drug to
another.
The Company believes that its contractual relationships with drug manufacturers
and retail pharmacies do not include the features that were viewed by
enforcement authorities as problematic in these settlement agreements. However,
no assurance can be given that the Company will not be subject to scrutiny or
challenge under one or more of these laws.
NETWORK ACCESS LEGISLATION. A majority of states now have some form of
legislation affecting the ability of the Company to limit access to a pharmacy
provider network or from removing network providers. Such legislation may
require the Company or its client to admit any retail pharmacy willing to meet
the plan's price and other terms for network participation ("any willing
provider" legislation); or providing that a provider may not be removed from a
network except in compliance with certain procedures ("due process"
13
<PAGE>
legislation). The Company has not been materially affected by these statutes
because it maintains a large network of over 46,000 retail pharmacies and will
admit any licensed pharmacy that meets the Company's credentialing criteria,
involving such matters as adequate insurance coverage, minimum hours of
operation, and the absence of disciplinary actions by the relevant state
agencies.
LEGISLATION IMPOSING PLAN DESIGN RESTRICTIONS. Some states have legislation that
prohibits the plan sponsor from implementing certain restrictive design
features. For example, some states provide that members of the plan may not be
required to use network providers, but must also be provided with benefits even
if they choose to use non-network providers ("freedom of choice" legislation).
Other states mandate coverage of certain benefits or conditions. Such
legislation does not generally apply to the Company, but it may apply to certain
of the Company's customers (HMOs and insurers). If such legislation were to
become widespread and broad in scope, it could have the effect of limiting the
economic benefits achievable through pharmacy benefit management.
LEGISLATION AFFECTING DRUG PRICES. Some states have adopted legislation
providing that a pharmacy participating in the state Medicaid program must give
the state the best price that the pharmacy makes available to any third party
plan ("most favored nation" legislation). Such legislation may adversely affect
the Company's ability to negotiate discounts in the future from network
pharmacies. Other states have enacted "unitary pricing' legislation, which
mandates that all wholesale purchasers of drugs within the state be given access
to the same discounts and incentives. Such legislation, if enacted in either
state, could adversely affect the Company's ability to negotiate discounts on
its prescription drugs to be dispensed by its mail service pharmacies.
MAIL PHARMACY REGULATION. The Company's mail service pharmacy is located in
Florida and the Company is licensed to do business as a pharmacy in that state.
Many of the states into which the Company delivers pharmaceuticals have laws and
regulations that require out-of-state mail service pharmacies to register with,
or be licensed by, the board of pharmacy or similar regulatory body in the
state. These states generally permit the mail service pharmacy to follow the
laws of the state within which the mail service pharmacy is located, although
one state also requires that the Company employ a pharmacist licensed in that
state. The Company has registered in every state in which, to the Company's
knowledge, such registration is required.
Other statutes and regulations impact the Company's mail service operations.
Federal statutes and regulations govern the labeling, packaging, advertising and
adulteration of prescription drugs and the dispensing of controlled substances.
The Federal Trade Commission requires mail order sellers of goods generally to
engage in truthful advertising, to stock a reasonable supply of the product to
be sold, to fill mail orders within thirty days, and to provide customers with
refunds when appropriate. The Company believes it is in compliance with all
requirements of the Federal Trade Commission.
REGULATION OF INFUSION THERAPY SERVICES. The Company's infusion therapy services
business is subject to many of the same or similar state laws and regulations
affecting the Company's pharmacy management business. In addition, some states
require that providers of infusion therapy services be licensed. The Company is
licensed as a home health agency , infusion pharmacy and pharmacy in Florida.
The Company is licensed as a pharmacy only, in Alabama. The Company believes
that it is in substantial compliance with such licensing requirements.
JCAHO, a non-profit, private organization, has established written standards for
health care organizations and home care services, including standards for
services provided by home infusion therapy companies. The Company's Florida
facility has received JCAHO accreditation. When accredited by JCAHO, the Company
can market infusion therapy services to Medicare and Medicaid programs. If the
Company expands its home infusion therapy services to other states or to
Medicaid programs, it may be required to comply with other applicable laws and
regulations.
14
<PAGE>
FUTURE REGULATION. The Company is unable to predict accurately what additional
federal or state legislation or regulatory initiatives may be enacted in the
future relating to the businesses of the Company or the health care industry in
general, or what effect any such legislation or regulations might have on the
Company. There can be no assurance that federal or state governments will not
impose additional restrictions or adopt interpretations of existing laws that
could have a material adverse effect on the Company's business or financial
position.
SERVICEMARKS AND TRADEMARKS
The Company has registered the servicemark "CompScript" with the United States
Patent and Trademark Office. The Company's rights to this servicemark will
continue so long as the Company complies with the usage, renewal filing and
other legal requirements relating to the renewal of service marks. The Company
is in the process of applying for registration of several other trademarks and
servicemarks. If the Company is unable to obtain any additional registrations,
the Company believes there would be no material adverse effect on the Company.
INSURANCE
The dispensing of pharmaceutical products by the Company's institutional and
mail service pharmacies, and the products and services provided in connection
with the Company's infusion therapy programs (including the associated nursing
services) may subject the Company to litigation and liability for damages. The
Company believes that its insurance protection is adequate for its present
business operations, but there can be no assurance that the Company will be able
to maintain its professional and general liability insurance coverage in the
future or that such insurance coverage will be available on acceptable terms or
be adequate to cover any or all potential product or professional liability
claims. A successful product or professional liability claim in excess of the
Company's insurance coverage could have a material adverse effect upon the
Company.
EMPLOYEES
As of September 17, 1996, the Company and its subsidiaries employed a total of
122 employees.
PRODUCT AND MARKET DEVELOPMENT
CompScript's pharmacy business engages in a continuing program for the
development of new services and the marketing thereof. While new service and new
market development are important factors for the growth of this business,
CompScript does not expect that any new service or marketing effort, including
those in the developmental stage, will require the investment of a material
portion of CompScript's assets.
MATERIALS/SUPPLIES
CompScript purchases pharmaceuticals through a wholesale distributor with whom
it has a prime vendor contract and, on an increasing basis, under contracts
negotiated directly with pharmaceutical manufacturers. The Company also is a
member of industry buying groups which contract with manufacturers for
discounted prices. The Company has numerous sources of supply available to it
and has not experienced any difficulty in obtaining pharmaceuticals or other
products and supplies used in the conduct of its business.
INVENTORIES
CompScript's pharmacies maintain adequate on-site inventories of pharmaceuticals
and supplies to ensure prompt delivery service to its customers. Inventories on
hand are not considered to be high beyond industry standards. The Company's
primary wholesale distributor also maintains local warehousing in most major
geographic markets in which the Company operates.
15
<PAGE>
ENVIRONMENTAL MATTERS
In operating its facilities, CompScript makes every effort to comply with
pollution control laws. No major difficulties have been encountered in effecting
compliance. No material capital expenditures for environmental control
facilities are expected. While CompScript cannot predict the effect which any
future legislation, regulations, or interpretations may have upon its
operations, it does not anticipate any changes that would have a material
adverse impact on its operations.
Item 2. DESCRIPTION OF PROPERTIES
The Company's principal offices are located in leased facilities in
Boca Raton, Florida. The Company has leased 864 square fee under a lease which
expires on January 31, 1997. The Company also maintains two pharmacies in
Alabama and Mississippi.
Item 3. LEGAL PROCEEDINGS
The Company is not a party to any material legal proceeding.
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITYHOLDERS
None.
Item 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Company's Common Stock, $.0001 par value, is traded on the NASDAQ
SmallCap Market under the symbol "CPRX." The following sets forth the range of
high and low closing bid prices for the Common Stock as reported on the NASDAQ
during each of the quarters presented. The quotations set forth below are
inter-dealer quotations, without retail mark-ups, mark-downs or commissions and
may not necessarily represent actual transactions. The quotations have been
adjusted for the Company's 1 to 8 reverse stock split on April 26, 1996.
<TABLE>
<CAPTION>
HIGH LOW
------ ------
<S> <C> <C>
1994
First Quarter................................................. $30.00 $26.00
Second Quarter................................................ 26.00 21.00
Third Quarter................................................. 23.00 21.00
Fourth Quarter................................................ 23.00 16.00
1995
First Quarter................................................. 20.25 11.00
Second Quarter................................................ 20.50 6.50
Third Quarter................................................. 7.25 3.50
Fourth Quarter................................................ 6.50 3.00
1996
First Quarter................................................. 8.75 3.00
Second Quarter................................................ 9.00 5.75
Third Quarter................................................. 7.25 4.125
</TABLE>
16
<PAGE>
The Company believes that as of June 12, 1996, there were over 300
record holders of the Company's Common Stock. The Company believes that there
are in excess of 300 beneficial holders of the Company's Common Stock.
The Company has not paid any cash dividends on its common stock and
currently does not intend to declare or pay cash dividends in the foreseeable
future. The Company presently intends to retain any earnings that may be
generated to provide funds for the operation of business.
Item 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS
GENERAL
Aldencare, Inc. (Aldencare) was incorporated under the laws of the
State of Florida on October 3, 1991. Aldencare was organized for the purpose of
supplying prescription pharmaceuticals, consulting, enteral and parental
therapies, and home health care services to long-term and alternate care
providers.
In June 1994, Aldencare, in a transaction accounted for as a purchase,
acquired substantially all of the assets of CompScript, Inc. (CompScript)
through the issuance of 399,740 shares of common stock to the former owners of
CompScript in exchange for all of the then outstanding common stock of
CompScript. The common stock of CompScript was retired, and its assets and
operations were merged with those of Aldencare. Effective January 1, 1995,
Aldencare changed its name to CompScript, Inc.
On April 26, 1996 Capital Brands, Inc. entered into a share exchange
agreement with CompScript-Boca (formerly CompScript, Inc.) whereby shareholders
of CompScript-Boca exchanged approximately 93% of the outstanding Common stock
of CompScript-Boca for approximately 80% of the outstanding Common shares of
Capital Brands, Inc. Capital Brands, Inc. is now principally engaged in the
business of providing comprehensive pharmacy management services as more fully
described below. Immediately prior to the share exchange agreement, Capital
Brands, Inc. divested itself of its 100% equity interest in Family Chicken,
Inc., International Fast Food Corporation and International Hotel Corporation.
The share exchange transaction was accounted for as a reverse purchase
acquisition of Capital Brands, Inc. by CompScript-Boca. The resulting entity
changed its name to CompScript, Inc. (the Company).
In connection with the expansion of its pharmacy management business on
May 31, 1996, the Company acquired 100% of the Common Stock of Delta Pharmacy
Services, Inc. ("Delta") in exchange for issuance of 666,350 shares of the
Company's Common Stock and on August 19, 1996 acquired 100% of the Common Stock
of SECURx, Inc. in exchange for 187,500 shares of the Company's Common Stock.
The acquisitions have been accounted for as poolings of interests.
The following unaudited pro forma summary presents the combined results
of operations as if the pooling-of-interest transactions had occurred on October
1, 1993. The pro forma financial information does not purport to be indicative
of the results of operations that would have occurred had the transactions taken
place at the beginning of the periods presented or of future results of
operations.
<PAGE>
ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION (CONTINUED)
GENERAL (CONTINUED)
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30, DECEMBER 31,
------------------ ------------------
1994 1995 1994 1995
---- ---- ---- ----
<S> <C> <C> <C> <C>
Total Sales:
CompScript $ 8,377,939 $10,485,269 $2,448,466 $ 2,903,723
Pooled entities 133,584 2,954,121 360,862 2,037,245
----------- ----------- ---------- -----------
Combined $ 8,511,523 $13,439,390 $2,809,328 $ 4,940,968
=========== =========== ========== ===========
Net Income(Loss):
CompScript $ 597,453 $ 30,595 $( 73,222) $(3,756,319)
Pooled entities ( 109,569) ( 131,563) ( 130,990) ( 161,453)
----------- ----------- ---------- -----------
Combined $ 487,884 $( 100,968) $( 204,212) $(3,917,772)
=========== =========== ========== ===========
Net Income(Loss)per share:
CompScript $ 0.06 $ 0.00 $( 0.01) $( 0.37)
Pooled entities ( 0.01) ( 0.01) ( 0.01) ( 0.02)
----------- ----------- ---------- -----------
Combined $ 0.05 $( 0.01) $( 0.02) $( 0.39)
=========== =========== ========== ===========
</TABLE>
As a result of the completion of the transactions described above the
Company is a comprehensive provider of pharmacy management services equipped to
both lower costs and improve the quality of care. The Company offers a broad
range of pharmacy, infusion therapy, consulting services, mail order, and
pharmacy benefit claim administration to managed care networks, long-term and
sub-acute care facilities, home health patients, and recipients of managed care.
The Company's proprietary pharmacy management capabilities combine sophisticated
clinical tools with the latest technologies in data bases and drug profiles. The
Company's network of participating retail pharmacies, along with its electronic
on-line adjudication system and a mail service dispensing facility, allow the
Company to offer a fully integrated pharmacy benefit management program.
On July 26, 1996, the Company agreed to sell its 1,125,000 shares of
Common Stock of QPQ Corporation ("QPQ") (which was acquired in the reverse
purchase acquisition of Capital Brands, Inc.) to a major shareholder of QPQ in
exchange for a non-recourse promissory note in the original principal amount of
$1,125,000, payable in full, including interest on July 4, 1997. The note may
be paid in whole or in part at any time during its term without penalty. The
1,125,000 shares will serve as collateral for the note subject to release upon
payment of the principal amount or portions thereof.
<PAGE>
ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION (CONTINUED)
YEAR ENDED SEPTEMBER 30, 1995 VS. SEPTEMBER 30, 1994
RESULTS OF OPERATIONS:
During the years ended September 30, 1995 and 1994, the Company
reported net income of $597,453 and $30,595 and reported net income per share of
$.34 and $.02, respectively.
Revenues for the years ended September 30, 1995 increased 25.2% to
$10,485,269, from $8,377,939 for the year ended September 30, 1994.
The increase in revenues for the year ended September 30, 1995 compared
to the year ended September 30, 1994 is primarily attributed to the Company's
steady internal growth resulting primarily from marketing efforts to new and
existing clients.
The Company's operations continued to produce internal growth through
marketing efforts to new and existing clients, and the growth and integration of
new and existing products and services.
Cost of sales for the year ended September 30, 1995 increased 39.2% to
$5,110,404 from $3,671,583 for the year ended September 30, 1994.
The increase in cost of sales for the year ended September 30, 1995
compared to the year ended September 30, 1994 is attributed to the additional
costs associated with the increase in sales described above.
Selling general and administrative expenses as a percentage of sales
for the years ended September 30, 1995 and 1994 were 47.3% and 42.1%. The
percentage increase in 1995 compared to 1994 is primarily attributable to the
increase in sales in the 1995 period as well as selling, general and
administrative expenses relating to the operations of the Company's pharmacy
benefits management division, which commenced operations in early 1995. In
addition, selling, general and administrative expenses for the year ended
September 30, 1995 include $197,450 of goodwill amortization as compared to
$65,817 for the year ended September 30, 1994.
The provision for doubtful accounts for the year ended September 30,
1995 totalled $213,102 as compared to $203,136 for the year ended September 30,
1994. The amount of the provision for each year was determined based upon an
evaluation of the collectibility of outstanding receivables during such periods.
Interest and other income for the years ended September 30, 1995 and
1994 consists of interest earned on temporary cash investments and has
fluctuated from period to period depending upon the amount of excess cash
available for investment.
Interest expense for the year ended September 30, 1995 increased by
$35,360 when compared to the year ended September 30, 1994, due to higher levels
of borrowings during 1995 as compared to 1994.
<PAGE>
ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION (CONTINUED)
THREE MONTHS ENDED DECEMBER 31, 1995 VS. DECEMBER 31, 1994
RESULTS OF OPERATIONS:
During the three month periods ended December 31,1995 and 1994, the
Company reported a net (loss) of $(3,756,319) and $(73,222) and reported a net
(loss) per share of $(1.84) and $(.04), respectively. The net loss and net loss
per share amounts for the three months ended December 31, 1995, include a
goodwill impairment charge of $3,636,362 or $(1.78) per share.
Revenues for the three months ended December 31, 1995 increased 18.6%
to $2,903,723, from $2,448,466 for the three months ended December 31, 1994.
The increase in revenues over the comparable prior year period is
primarily attributed to the Company's steady internal growth resulting primarily
from marketing efforts to new and existing clients.
The Company's operations continued to produce internal growth through
marketing efforts to new and existing clients, and the growth and integration of
new and existing products and services.
Cost of sales for the three months ended December 31, 1995 increased
16.4% to $1,461,453 from $1,255,577 for the three months ended December 31,
1994.
The increase in cost of sales over the comparable prior year period is
attributed to the additional costs associated with the increase in sales
described above.
Selling general and administrative expenses as a percentage of sales
for the three month periods ended December 31, 1995 and 1994 were 52.3% and
46.5%. The percentage increase in the comparative three month period is
primarily attributable to the increase in sales for such periods as well as the
selling, general and administrative expenses relating to the operations of the
Company's pharmacy benefits management division, which commenced operations in
early 1995.
The provision for doubtful accounts for the three months ended December
31, 1995 totaled $74,448 as compared to $143,102 for the three months ended
December 31, 1994. The amount of the provision for each period was determined
based upon an evaluation of the collectibility of outstanding receivables during
such periods.
At December 31, 1995, the Company recognized a goodwill impairment
charge of $3,636,362 with no associated tax benefit, related to the 1994
acquisition of its Ohio Division. The Ohio Division was purchased to be the
Company's entry into the workers compensation, pharmacy benefits management
(PBM) line of business. During the three months ended December 31, 1995, the
contracts attributed to the Ohio Division generated minimal revenue due in part
to the nonexclusive nature of the contracts. In addition, the
<PAGE>
ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION (CONTINUED)
THREE MONTHS ENDED DECEMBER 31, 1995 VS. DECEMBER 31, 1994
RESULTS OF OPERATIONS(CONTINUED):
inability of the Ohio Division to convert existing relationships with
prospective clients into new PBM contracts or to secure new prospective clients
had contributed to significant operating losses and negative cash flows relative
to the Ohio Division. Based on the continuing poor financial results and the
failure to obtain new contracts, the Company believes that the PBM business
acquired with the Ohio Division will not generate positive cash flows in the
foreseeable future and the strategy to implement this line of business within
the Ohio Division, will no longer be a priority of the Company. Therefore, the
Company wrote-off the unamortized carrying value of the goodwill of $3,636,362
in December, 1995.
Interest and other income for the three months ended December 31, 1995
and 1994 periods presented consists of interest earned on temporary cash
investments and has fluctuated from period to period depending upon the amount
of excess cash available for investment.
Interest expense in the three month period ended December 31, 1995
increased by $11,282 due to higher levels of borrowings during 1995 as compared
to 1994.
LIQUIDITY AND CAPITAL RESOURCES:
At December 31, 1995, the Company had working capital of $1,801,277 and
cash and cash equivalents of $263,033.
Net cash used in operating activities for the three months ended
December 31, 1995 was $71,016 compared to net cash used in operating activities
for the three months ended December 31, 1994 of $126,905. The decrease in cash
used in operating activities in the 1995 period of $55,889 results primarily
from larger levels of accounts receivable and inventory relating to increased
sales offset by increases in trade liabilities relating to the timing of payment
of vendor payables.
Net cash used in investment activities for the three months ended
December 31, 1995 in the amount of $57,338 consisted of net purchases of
property and equipment, which decreased by $50,411 when compared with the three
months ended December 31, 1994.
Net cash provided by financing activities for the three months ended
December 31, 1995 was $37,786 as compared to net cash provided by financing
activities of $3,962 for the three months ended December 31, 1994. During the
three months ended December 31, 1995, the Company received proceeds from
borrowings under its line of credit of $92,563. Repayments of outstanding credit
obligations for the three months ended December 31, 1995 were $27,277 as
compared to $36,238 for the three month period ended December 31, 1994.
Repayments of leases and other indebtedness decreased due to final payment in
late 1995 of certain obligations.
<PAGE>
ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION (CONTINUED)
LIQUIDITY AND CAPITAL RESOURCES (CONTINUED):
In May 1995, the Company entered into the line-of credit agreement
which permits borrowings up to $750,000. The line of credit is due upon demand
and is secured by substantially all of the assets of the Company. Interest is
payable monthly at prime plus .25% (9.00% and 8.75% at September 30, 1995 and
December 31, 1995, respectively) with a .25% fee on the unused portion of the
line. Approximately $35,000 and $122,000 is outstanding at September 30, 1995
and December 31, 1995, respectively.
The Company believes that its cash and available sources of capital
through exercise of outstanding options and warrants as well as the availability
of borrowings under its line of credit are sufficient to meet its normal
operating requirements through June 30, 1997.
Item 7. FINANCIAL STATEMENTS
See "Index to Financial Statements" for the financial statements
included in this Form 10-KSB.
Item 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
17
<PAGE>
Part III
Item 9. DIRECTOR'S, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT
The following table sets forth certain information concerning the
current directors and the executive officers of the Company:
Name Age Title
- -------------------------------------------------------------------------------
Brian A. Kahan ................ 44 Chairman of the Board, Chief Executive
Officer and President of the Company
Martha M. Little .............. 35 Vice President and Director
Gary Splain ................... 46 Treasurer and Secretary
Gerard N. Altieri ............. 66 Director
Malcolm Leonard ............... 53 Director
Robert Edelheit ............... 56 Director
Paul E. Heimberg............... 45 Director
BRIAN A. KAHAN has been a Chairman, Chief Executive Officer and
President of the Company since April 1996. In October 1991, Mr. Kahan founded
Aldencare and served as its Chief Executive Officer and became Chief Executive
Officer of CompScript when it merged with Aldencare in 1994. Mr. Kahan has a
B.S. in Pharmacy from the University of Maryland, School of Pharmacy. Mr. Kahan
is currently President of the American Society of Consultant Pharmacists and
serves on the LTC Commission for the State of Florida. Mr. Kahan is presently a
clinical instructor for the University of Florida and Nova Southeastern College
of Pharmacy and is a trustee for the Florida Pharmacy Foundation.
MARTHA M. LITTLE has been the Vice President and Director of the
Company since April 1996. Ms. Little has been with Aldencare and CompScript
since October 1991, serving as Pharmacy Manager in 1991 until 1993. Ms. Little
was promoted to Vice President in February 1992 and was appointed a Director of
CompScript in January 1993. Ms. Little is a member of the American Society of
Consultant Pharmacists and received a B.S. from the University of Florida and a
post-graduate doctor of pharmacy degree from Nova Southeastern University.
GARY SPLAIN has served as the Treasurer and Secretary of the Company
since April 1996. Mr. Splain has served as the comptroller of CompScript since
1992. From 1991 to 1992 Mr. Splain was the business office manager for a local
branch of a national institutional pharmacy. Mr. Splain received a B.A. in
accounting from Queens College.
GERARD N. ALTIERI has been Director of the Company since April 1996.
Mr. Altieri was President of G.N. Altieri & Associates from 1970 until 1990.
From 1986 to 1993 Mr. Altieri was President of Insurex a pharmacy benefit
management company. In 1993, Mr. Altieri formed CompScript, Inc. and began the
management of prescription drugs in the field of workman's compensation. Mr.
Altieri received a B.A. in Business Administration from Fairfield University and
received his Charter Life Underwriter's Designation from the College of Life
Underwriter.
MALCOLM LEONARD has served as a Director of the Company since April
1996. Mr. Leonard is a Certified Public Accountant and has been the managing
partner of Leonard & Danzinger, CPA's since 1975.
18
<PAGE>
Mr. Leonard is a member of the American Institute of Certified Public
Accountants and the Florida Institute of Certified Public Accountants. Mr.
Leonard received a B.S. from Farleigh Dickinson University.
ROBERT EDELHEIT has served as a Director of the Company since April
1996. Mr. Edelheit is President of United Group Programs, employee benefit sales
and consulting firm with offices in Boca Raton, Atlanta and Philadelphia. Mr.
Edelheit received his B.S. in Business from the State University of New York.
Mr. Edelheit is editor and publisher of the newsletter, SYNOPSIS, a fax digest
with an emphasis on employee benefits. Mr. Edelheit has been an Associate
Professor at Florida Atlantic University in Boca Raton, Florida and speaks
nationally on employee benefits.
PAUL HEIMBERG has served as Director of the Company since April 1996.
Mr. Heimberg is a partner with the law firm of Heimberg & Lumer, in Boca Raton,
Florida since November, 1995. Previously Mr. Heimberg was a partner with the
firm of Heimberg, Heimberg, Rader & Levenstein, P.A. from 1990 to 1995. Mr.
Heimberg received his B.A. from the University of Wisconsin and his J.D. from
Boston University Law School.
The Company's officers are elected annually by the Company's Board of
Directors and serve at the discretion of the Company's Board of Directors. The
Company pays each non-employee director a fee to be determined for each meeting
of the Company's Board of Directors, or committee thereof, attended and
reimburses all directors for their expenses in connection with their activities
as directors of the Company. Directors of the Company who are also employees of
the Company do not receive additional compensation for their services as
directors.
Item 10. EXECUTIVE COMPENSATION
SUMMARY COMPENSATION TABLE
The following table sets forth the aggregate compensation paid to Brian
A. Kahan (the "Named Executive Officer") by the Company. None of the other
executive officers of the Company, were paid a total annual salary and bonus for
the 1995 fiscal year which was $100,000 or more.
<TABLE>
<CAPTION>
LONG-TERM
ANNUAL COMPENSATION COMPENSATION
----------------------- ------------
OTHER NUMBER OF
FISCAL ANNUAL OPTIONS ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY COMPENSATION GRANTED COMPENSATION
- --------------------------- ----- ------ ------------ --------- ------------
<S> <C> <C> <C> <C> <C>
Brian A. Kahan, 1995 $180,000 $41,000 None $11,000
Chief Executive Officer
</TABLE>
The Company entered into an agreement with Mr. Kahan, amended and
restated on August 19, 1996, which provides that he shall serve as Chief
Executive Officer and Chairman of the Board of Directors for an initial term of
five (5) years, which may be extended for up to three (3) additional one (1)
year terms. Mr. Kahan's annual salary for the first year shall be $300,000
subject to annual increases equal to the greater of the percentage increase in
the consumer price index or six percent (6%) of the executive's previous year's
base salary. Pursuant to the Employment Agreement, Mr. Kahan is required to
devote substantially all his business time and attention to the business and
affairs of the Company. Mr. Kahan is entitled to a bonus equal to ten percent
(10%) of the Company's pre-tax profits for each year of the Agreement. Mr. Kahan
is entitled to certain fringe benefits including an automobile allowance and
reimbursements for charitable donations or contributions in an amount not to
exceed $25,000. In the event that Mr. Kahan's employment is terminated by the
Company other than for cause, he shall
19
<PAGE>
receive either a lump sum equal to his total compensation and benefits for the
remaining balance of the term of the agreement, reduced to present value or such
payments on a monthly basis.
Mr. Kahan held no unexercised stock options at December 31, 1995 and no
stock options were exercised by the named executive officer during the period
ended December 31, 1995.
Item 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of September 1, 1996,
information with respect to the beneficial ownership of the Company's Common
Stock by (i) each person who is known by the Company to own beneficially more
than 5% of its Common Stock, (ii) each director and nominee for director, (iii)
each Named Executive Officer (as defined herein), and (iv) all directors and
executive officers as a group:
<TABLE>
<CAPTION>
PERCENTAGE OF
AMOUNT AND NATURE OF OUTSTANDING
NAME AND ADDRESS OF BENEFICIAL OWNER(1) BENEFICIAL OWNERSHIP(2) SHARES OWNED(2)
- --------------------------------------- ----------------------- ---------------
<S> <C> <C>
Brian A. Kahan.............................. 4,435,653(3) 41.4%
Gerard N. Altieri........................... 723,733 6.8%
Martha M. Little............................ 243,212(4) 2.3%
Malcolm Leonard............................. 14,894(5) *
Robert Edelheit............................. 48,730 *
Paul Heimberg............................... 161,782(6) 1.5%
Gary Splain................................. 315 *
All directors and executive officers
as a group (seven persons).................. 5,628,319(7) 52.6%
</TABLE>
- ----------------------------
* Less than 1%.
(1) Unless otherwise indicated, the address of each of the listed
beneficial owners identified is 1225 Broken Sound Parkway, N.W., Suite
A, Boca Raton, Florida 33451. Unless otherwise noted, the Company
believes that all persons named in the table have sole voting and
investment power with respect to all the shares of Common Stock
beneficially owned by them.
(2) A person is deemed to be the beneficial owner of securities that can be
acquired by such person within 60 days from the date of this Proxy
Statement upon the exercise of warrants or options. Each beneficial
owner's percentage ownership is determined by assuming that warrants or
options that are held by such person (but not those held by any other
person) and that are exercisable within 60 days from the date of this
Proxy Statement have been exercised.
(3) Includes 3,759,328 shares of Common Stock held as Trustee for the Kahan
Family Revocable Trust. Also includes 673,125 shares of Common Stock
held by Mr. Kahan as custodian for his three minor children, Shannon A.
Kahan (224,375 shares of Common Stock), Amanda R. Kahan (224,375 shares
of Common Stock) and Heather S. Kahan (224,375 shares of Common Stock).
(4) Includes 15,594 shares of Common Stock held by Mrs. Little as custodia
for her son Nathan D. Little.
20
<PAGE>
(5) Includes 3,898 shares of Common Stock held by Mr. Leonard in a Joint
Tenancy with a Right of Survivorship ("JTWROS") with his sister Corinne
Leonard, 5,848 shares of Common Stock held by Mr. Leonard in a JTWROS
with his daughter Jennifer Gottlieb and 5,848 shares of Common Stock
held by Mr. Leonard in a JTWROS with his daughter Shari Leonard.
(6) Includes 3,898 shares of Common Stock held by Mr. Heimberg's wife,
Denise Heimberg, (7) See notes 3 - 6 above.
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's directors and executive officers, and persons who own more than ten
percent of the Company's outstanding Common Stock to file with the Securities
and Exchange Commission (the "SEC") initial reports of ownership and reports of
changes in ownership of Common Stock. Such persons are required by SEC
regulation to furnish the Company with copies of all such reports they file.
To the Company's knowledge, based solely on a review of the copies of
such reports furnished to the Company and written representations that no other
reports were required, all Section 16(a) filing requirements applicable to its
officers, directors and greater than ten percent beneficial owners have been
complied with.
Item 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None.
21
<PAGE>
PART IV
Item 13. EXHIBITS AND REPORTS ON FORM 8-K.
A. EXHIBITS:
EXHIBIT DESCRIPTION
------- -----------
3.1 CompScript's Articles of Incorporation (1)
3.2 Amendments to CompScript's Articles of Incorporation dated
April 24, 1996, 1996 and July 3, 1996*
3.3 CompScript's Bylaws(1)
4.1 Form of CompScript's Common Stock Certificate (2)
4.2 Form of Warrant Agreement, dated June 14, 1990, between
CompScript and Continental Stock Transfer & Trust
Company and Form of Warrants (10.1)(3)
4.3 Form of CompScript Warrant Certificates (2)
10.1 CompScript 1996 Stock Option Plan (4)
10.2 Share Exchange Agreement, dated February 29, 1996, among
Capital Brands, CompScript, Inc. and certain shareholders of
CompScript, Inc. (10.1)(5)
10.3 Employment Agreement dated August 19, 1996 between
CompScript and Brian A. Kahan *
10.4 Stock Purchase Agreement dated May 31, 1996 between
CompScript and the Shareholders of Delta Pharmacy Services,
Inc.(10.3)(6)
10.5 Stock Purchase Agreement dated August 19, 1996 between
Delta CompScript and the Shareholders of SecurX,
Inc.(10.1)(7)
22.1 CompScript's Subsidiaries*
23.1 Consent of Ernst and Young LLP*
- ------------------------
(1) Incorporated by reference to the exhibit of the same number
filed with CompScript's Registration Statement on Form S-18
(No. 33-33988-A).
(1) Incorporated by reference to the exhibit of the number
indicated filed with CompScript's Form 8-K dated September 2,
1994.
(2) Incorporated by reference to the exhibit of the same number
filed with CompScript's Form 10- KSB for the year ended
December 31, 1994.
(3) Incorporated by reference to exhibit number 19.1 of
CompScript's Registration Statement on Form S-18
(No.33-33988-A).
(4) Incorporated by reference to Appendix B of CompScript's Proxy
Statement for the year ended 1995.
(5) Incorporated by reference to the exhibit of the number
indicated filed with CompScript's Form 8-K dated March 14,
1996.
(6) Incorporated by reference to the exhibit of the number
indicated filed with CompScript's Form 8-K dated June 14,
1996.
(7) Incorporated by reference to the exhibit of the number
indicated filed with Compscript's 8-K dated August 30, 1996.
* Filed herewith.
B. REPORTS ON FORM 8-K:
None.
22
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act
of 1934, the Registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
COMPSCRIPT, INC.
By: /S/ BRIAN A. KAHAN
------------------------------------------
Brian A. Kahan, Chairman of the Board, Chief
Executive Officer [Principal Executive Officer]
By: /S/ GARY SPLAIN
------------------------------------------
Gary Splain, Treasurer
[Principal Financial and Accounting Officer]
In accordance with the Securities Exchange Act of 1934, this report has
been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated:
DATE: October 11, 1996 By: /S/ BRIAN A. KAHAN
---------------
Brian A. Kahan, Director
DATE: October 11, 1996 By: /S/ GERARD H. ALTIERI
-----------------------------------
Gerard H. Altieri, Director
DATE: October 11, 1996 By: /S/ PAUL HEIMBERG
-----------------------------------
Paul Heimberg, Director
DATE: October 11, 1996 By: /S/ MARTIN M. LITTLE
-----------------------------------
Martin M. Little, Director
DATE: October 11, 1996 By: /S/ ROBERT EDELHEIT
-----------------------------------
Robert Edelheit, Director
DATE: October 11, 1996 By: /S/ MALCOLM LEONARD
-----------------------------------
Malcolm Leonard, Director
23
<PAGE>
TRANSITION REPORT ON FORM 10-KSB
ITEM 7
LIST OF FINANCIAL STATEMENTS
THREE MONTHS ENDED DECEMBER 31, 1995
COMPSCRIPT, INC.
BOCA RATON, FLORIDA
<PAGE>
Form 10-KSB-Item 7
List of Financial Statements
The following financial statements of CompScript, Inc. are included in Item 7:
Balance Sheets--September 30, 1994 and 1995 and December 31, 1995
Statements of Operations--Years ended September 30, 1994 and 1995 and the
three months ended December 31, 1994 and 1995
Statements of Shareholders' Equity--Years ended September 30, 1994 and 1995
and the three months ended December 31, 1994 and 1995
Statements of Cash Flows--Years ended September 30, 1994 and 1995 and the
three months ended December 31, 1994 and 1995
Notes to Financial Statements--December 31, 1995
<PAGE>
Report of Independent Certified Public Accountants
The Board of Directors
and Shareholders
CompScript, Inc.
We have audited the balance sheets of CompScript, Inc. as of September 30, 1994
and 1995, and December 31, 1995 and the related statements of operations,
shareholders' equity and cash flows for each of the two years in the period
ended September 30, 1995 and for the three months ended December 31, 1994 and
1995. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of CompScript, Inc. at September
30, 1994 and 1995, and December 31, 1995 and the results of its operations and
its cash flows for each of the two years in the period ended September 30, 1995
and for the three months ended December 31, 1994 and 1995, in conformity with
generally accepted accounting principles.
West Palm Beach, Florida
August 23, 1996
1
<PAGE>
CompScript, Inc.
Balance Sheets
<TABLE>
<CAPTION>
SEPTEMBER DECEMBER 31,
1994 1995 1995
-------------------------------------------
<S> <C> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 614,089 $ 353,601 $ 263,033
Accounts receivable (net of allowances of $-0-, $-0-
and $66, 845 at September 30, 1994 and 1995, and
December 31, 1995, respectively) 1,685,843 1,713,145 1,728,408
Inventory 316,503 440,088 483,019
Prepaid and other receivables 11,448 52,134 58,464
-------------------------------------------
Total current assets 2,627,883 2,558,968 2,532,924
Property and equipment, net 786,496 904,784 905,500
Other assets:
Goodwill, less accumulated amortization of $65,817,
$263,267 and $-0- at September 30, 1994 and 1995,
and December 31, 1995, respectively 3,883,174 3,685,724 -
Other 201,938 201,463 282,766
-------------------------------------------
Total other assets 4,085,112 3,887,187 282,766
-------------------------------------------
Total assets $7,499,491 $7,350,939 $3,721,190
===========================================
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 323,738 $ 258,707 $ 366,659
Accrued salaries and benefits 253,064 177,565 93,660
Accrued expenses 5,981 - 9,663
Accrued pharmaceuticals dispensed by third parties - 36,127 63,701
Income taxes payable 89,040 - -
Leases payable 86,650 66,586 57,951
Line of credit - 34,889 121,756
Notes payable 14,310 18,469 18,257
-------------------------------------------
Total current liabilities 772,783 592,343 731,647
Long-term debt:
Leases payable 42,808 53,259 45,357
Notes payable 21,810 12,652 7,820
-------------------------------------------
Total long-term debt 64,618 65,911 53,177
-------------------------------------------
Total liabilities 837,401 658,254 784,824
Shareholders' equity:
Common stock, no par value--10,000,000 shares
authorized, 2,039,840 shares issued and
outstanding in 1994 and 1995 5,499,153 5,499,153 5,499,153
Retained earnings (accumulated deficit) 1,162,937 1,193,532 (2,562,787)
-------------------------------------------
Total shareholders' equity 6,662,090 6,692,685 2,936,366
-------------------------------------------
Total liabilities and shareholders' equity $7,499,491 $7,350,939 $3,721,190
===========================================
</TABLE>
SEE ACCOMPANYING NOTES.
2
<PAGE>
CompScript, Inc.
Statements of Operations
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
1994 1995 1994 1995
---------------------------------------------------------------
<S> <C> <C> <C> <C>
Sales $8,377,939 $10,485,269 $2,448,466 $ 2,903,723
Cost of sales 3,671,583 5,110,404 1,255,577 1,461,453
---------------------------------------------------------------
Gross profit 4,706,356 5,374,865 1,192,889 1,442,270
Selling, general and administrative
expenses 3,523,230 4,961,478 1,138,878 1,519,644
Provision for doubtful accounts 203,136 213,102 143,102 74,448
Goodwill impairment charge - - - 3,636,362
---------------------------------------------------------------
Total operating expenses 3,726,366 5,174,580 1,281,980 5,230,454
---------------------------------------------------------------
Operating income (loss) 979,990 200,285 (89,091) (3,788,184)
Other:
Interest and other income 25,345 21,995 4,565 3,722
Interest expense (13,414) (48,774) - (11,282)
---------------------------------------------------------------
Income (loss) before income taxes 991,921 173,506 (84,526) (3,795,744)
Provision (benefit)
for income taxes 394,468 142,911 (11,304) (39,425)
---------------------------------------------------------------
Net income (loss) $ 597,453 $ 30,595 $ (73,222) $(3,756,319)
===============================================================
Net income (loss) per share $ 0.34 $ 0.02 $ (0.04) $ (1.84)
===============================================================
Weighted average shares outstanding 1,773,347 2,039,840 2,039,840 2,039,840
===============================================================
</TABLE>
SEE ACCOMPANYING NOTES.
3
<PAGE>
CompScript, Inc.
Statements of Shareholders' Equity
<TABLE>
<CAPTION>
RETAINED
COMMON STOCK EARNINGS TOTAL
---------------------- (ACCUMULATED SHAREHOLDERS'
SHARES AMOUNT DEFICIT) EQUITY
--------------------------------------------------------------------
<S> <C> <C> <C> <C>
Balance at September 30, 1993 1,640,100 $1,501,753 $ 565,484 $2,067,237
Net income - - 597,453 597,453
Stock issued for acquisition 399,740 3,997,400 - 3,997,400
-------------------------------------------------------------------
Balance at September 30, 1994 2,039,840 5,499,153 1,162,937 6,662,090
Net loss - - (73,222) (73,222)
-------------------------------------------------------------------
Balance at December 31, 1994 2,039,840 5,499,153 1,089,715 6,588,868
Net income - - 103,817 103,817
-------------------------------------------------------------------
Balance at September 30, 1995 2,039,840 5,499,153 1,193,532 6,692,685
Net loss - - (3,756,319) (3,756,319)
-------------------------------------------------------------------
Balance at December 31, 1995 2,039,840 $5,499,153 $(2,562,787) $2,936,366
===================================================================
</TABLE>
SEE ACCOMPANYING NOTES.
4
<PAGE>
CompScript, Inc.
Statements of Cash Flows
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
1994 1995 1994 1995
-----------------------------------------------------------
<S> <C> <C> <C> <C>
OPERATING ACTIVITIES
Net income (loss) $ 597,453 $ 30,595 $ (73,222) $(3,756,319)
Adjustments to reconcile net income (loss) to net
cash provided (used) by operating activities:
Depreciation and amortization of leasehold
improvements 151,906 199,568 39,301 56,622
Gain on sale of property and equipment (4,052) (2,270) - -
Amortization of organization costs and goodwill 68,302 199,935 49,984 49,984
Goodwill impairment charge - - - 3,636,362
Provision for doubtful accounts 203,136 213,102 143,102 74,448
Changes in operating assets and liabilities:
Accounts receivable (926,465) (240,404) (32,067) (89,711)
Inventory (21,422) (123,585) 80,184 (42,931)
Prepaid and other receivables (4,967) (40,686) 136 (6,330)
Other assets (25,472) (2,010) (40,220) (54,425)
Accounts payable and accrued expenses 80,813 (199,424) (294,101) 61,284
-----------------------------------------------------------
Net cash provided (used) by operating activities 119,232 34,821 (126,905) (71,016)
INVESTING ACTIVITIES
Purchase of property and equipment (338,270) (261,147) (107,749) (57,338)
Other assets (180,500) - - -
-----------------------------------------------------------
Net cash used in investing activities (518,770) (261,147) (107,749) (57,338)
FINANCING ACTIVITIES
Proceeds from line of credit - 37,154 - 92,563
Repayment of line of credit - - - (5,696)
Proceeds from notes payable 45,904 50,407 40,200 -
Repayment of notes and leases payable (175,825) (121,723) (36,238) (21,581)
Payment of deferred acquisition costs - - - (27,500)
-----------------------------------------------------------
Net cash (used) provided by financing activities (129,921) (34,162) 3,962 37,786
-----------------------------------------------------------
Net decrease in cash and cash equivalents (529,459) (260,488) (230,692) (90,568)
Cash and cash equivalents at beginning of period 1,143,548 614,089 614,089 353,601
-----------------------------------------------------------
Cash and cash equivalents at end of period $ 614,089 $ 353,601 $ 383,397 $ 263,033
===========================================================
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for income taxes $ 600,243 $ 272,444 $ - $ -
===========================================================
Cash paid for interest $ 13,414 $ 28,203 $ - $ 6,139
===========================================================
Fixed assets acquired pursuant to capital lease
obligations $ 81,496 $ 54,550 $ - $ -
===========================================================
SEE ACCOMPANYING NOTES.
</TABLE>
5
<PAGE>
CompScript, Inc.
Notes to Financial Statements
September 30, 1995
1. THE COMPANY
Aldencare, Inc. (the Company) was incorporated under the laws of the State of
Florida on October 3, 1991. The Company was organized for the purpose of
supplying prescription pharmaceuticals, consulting, enteral and parental
therapies, and home health care services to long-term and alternate care
providers.
In June 1994, the Company acquired substantially all of the assets of
CompScript, Inc. (CompScript) through the issuance of 399,740 shares of common
stock to the former owners of CompScript in exchange for all of the then
outstanding common stock of CompScript. The common stock of CompScript was
retired, and its assets and operations were merged with those of the Company;
although they are segregated in the accounting records of the Company as the
Ohio Division. Effective January 1, 1995, the Company changed its name to
CompScript, Inc.
An additional 399,740 shares of common stock were placed in escrow pending the
future attainment of specified operating results by the Ohio Division as
outlined in the acquisition agreement. This transaction was recorded as a
purchase because of the contingent issuance of additional shares of common stock
based upon the future operations of the Ohio Division.
As a result of this acquisition, fixed assets of $48,409 were acquired and
goodwill in the amount of $3,948,991 was recorded. The 399,740 shares issued
were valued at $10 per share which was the price paid by outside investors in
the most recent offering of common stock. The value of the 399,740 shares placed
in escrow were never included in the purchase price because there was no
assurance that the Ohio Division would attain the specified operating results
within the required time period. In February 1996, the former owners of
CompScript and management of the Company mutually agreed that the contingent
shares held in escrow were to be permanently eliminated.
The Ohio Division provides insurance administration services and promotional
services for its mail-order pharmacy division in the State of Ohio. The
operating results from June 2, 1994 through September 30, 1994 have been
included in the statement of income for the year ended September 30, 1994.
6
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
1. THE COMPANY (CONTINUED)
On April 26, 1996, shareholders who previously owned approximately 93% of the
Company exchanged their shares of the Company's Common Stock for 7,394,982
common shares (representing an 80% interest) of Capital Brands, Inc. (Capital),
a publicly-held company involved in the development of consumer-based businesses
in the Republic of Poland (the Acquisition). This exchange was structured as a
tax-free reorganization. The Acquisition was accounted for as a reverse purchase
of Capital by the Company pursuant to which the Company was recapitalized to
include the assets and liabilities of Capital revalued to reflect the market
value of Capital's net tangible assets at the date of the Acquisition,
consisting of cash and marketable equity securities. As Capital had no
operations as of the Acquisition date, no pro forma financial information is
presented.
On May 31, 1996, in a transaction accounted for as a pooling of interests, the
Company acquired Delta Pharmacy Services, Inc. (Delta). In connection with the
transaction, the Company exchanged 666,350 shares of the Company's common stock
for all of the outstanding common stock of Delta. Delta is in the business of
supplying prescription pharmaceuticals, consulting and enteral and parental
therapies to long-term and alternate care providers.
On August 19, 1996, in a transaction accounted for as a pooling of interests,
the Company acquired SECURx, Inc. (SECURx). In connection with the transaction,
the Company exchanged 187,500 shares of the Company's common stock for all of
the outstanding common stock of SECURx. SECURx is in the business of selling and
distributing prescription drugs to the general public through corporate
sponsored benefit plans of employers located in the northeastern United States.
The following unaudited pro forma summary presents the combined results of
operations as if the pooling-of-interest transactions had occurred on October 1,
1993. The pro forma financial information does not purport to be indicative of
the results of operations that would have occurred had the transactions taken
place at the beginning of the periods presented or of future results of
operations.
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
-----------------------------------------------------------------
1994 1995 1994 1995
-----------------------------------------------------------------
<S> <C> <C> <C> <C>
Total sales:
CompScript $8,377,939 $10,485,269 $2,448,466 $2,903,723
Pooled entities 133,584 2,954,121 360,862 2,037,245
-----------------------------------------------------------------
Combined $8,511,523 $13,439,390 $2,809,328 $4,940,968
=================================================================
</TABLE>
7
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
-------------------------------- ---------------------------------
1994 1995 1994 1995
--------------- ---------------- ----------------- ---------------
<S> <C> <C> <C> <C>
Net income (loss):
CompScript $ 597,453 $ 30,595 $ (73,222) $(3,756,319)
Pooled entities (109,569) (131,563) (130,990) (161,453)
--------------- ---------------- ----------------- ---------------
Combined $ 487,884 $ (100,968) $ (204,212) $(3,917,772)
=============== ================ ================= ===============
Net income (loss) per share:
CompScript $ 0.06 $ 0.00 $ (0.01) $ (0.37)
Pooled entities (0.01) (0.01) (0.01) (0.02)
--------------- ---------------- ----------------- ---------------
Combined $ 0.05 $ (0.01) $ (0.02) $ (0.39)
=============== ================ ================= ===============
</TABLE>
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
CASH EQUIVALENTS
The Company considers all highly liquid investments with an original maturity of
three months or less, when acquired, to be cash equivalents.
INVENTORY
Inventory is stated at the lower of cost or market. Cost is determined by the
first-in, first-out method, and market represents the lower of replacement cost
or estimated net realizable value.
PROPERTY AND EQUIPMENT
Property and equipment is recorded at cost. Depreciation of equipment and
amortization of leasehold improvements is computed using the straight-line
method over the estimated useful lives of the related assets, ranging from five
to seven years. Expenditures for maintenance and repairs are charged to expense
as incurred.
REVENUE RECOGNITION
Revenue and the related cost of sales are recognized when services are provided
or products are delivered.
8
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
INCOME TAXES
Deferred income taxes are determined based on the differences between the
financial statement and tax basis of assets and liabilities using the enacted
tax rates for the years in which the taxes are expected to be paid or recovered.
NET INCOME PER SHARE
Net income per share is calculated using the weighted average number of common
shares outstanding as the effect of the Company's outstanding common stock
equivalents was antidilutive for all periods presented.
FASB STATEMENT NO. 121
In March 1995, the FASB issued Statement No. 121, ACCOUNTING FOR THE IMPAIRMENT
OF LONG-LIVED ASSETS AND FOR LONG-LIVED ASSETS TO BE DISPOSED OF. This
statement, which is effective for the Company's fiscal year ending December 31,
1996, requires that long-lived assets and certain intangibles to be held and
used by the Company be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. If the estimated undiscounted cash flows that are expected to
result from the use of the asset are less than the carrying amount of the asset,
an impairment loss is recorded equal to the excess of the carrying amount over
the fair value of the assets. The Company will review for impairment of its
long-lived assets in 1996 using the methodology prescribed by FASB Statement No.
121, and, based on current circumstances, does not believe the effect of
adoption will be material.
FASB STATEMENT NO. 123
In October 1995, the FASB issued Statement No. 123, ACCOUNTING FOR STOCK-BASED
COMPENSATION. The new standard, which is effective for the Company's fiscal year
ending December 31, 1996, encourages companies to use the fair value method of
accounting for the issuance of stock options and other equity instruments. Under
the fair value method, compensation cost is measured at the grant date based on
the fair value of the award and is recognized over the service period, which is
usually the vesting period. Pursuant to FASB
9
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Statement No. 123, companies are also permitted to continue to account for
employee stock-based transactions under Accounting Principles Board (APB)
Opinion No. 25, ACCOUNTING FOR STOCK ISSUED TO EMPLOYEES, but would be required
to disclose in a note to the financial statements pro forma net income and per
share amounts as if the Company had applied the new method of accounting.
Currently, the Company has elected to follow APB Opinion No. 25 to account for
its employee stock options. Under APB Opinion No. 25, if the exercise price of
the Company's employee stock options equals the market price of the underlying
stock on the date of grant, no compensation expense is recognized.
The Company has not yet determined if it will elect to change its method of
accounting for the issuance of stock options and other equity instruments to the
fair value method, nor has it determined the effect the new standard will have
on its operating results and per share results should it elect to make such a
change.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements.
Estimates also affect the reported amounts of revenue and expenses during the
reporting period. Actual result could differ from those estimates.
3. PROPERTY AND EQUIPMENT
Property and equipment consists of the following:
<TABLE>
<CAPTION>
SEPTEMBER 30 DECEMBER 31,
1994 1995 1995
------------------------------------------------
<S> <C> <C> <C>
Furniture and equipment $ 712,772 $ 952,785 $1,010,123
Automobiles 85,728 99,673 99,673
Leasehold improvements 49,407 58,865 58,865
Assets under capital leases 211,782 266,222 266,222
------------------------------------------------
1,059,689 1,377,545 1,434,883
Less accumulated depreciation (273,193) (472,761) (529,383)
------------------------------------------------
$ 786,496 $ 904,784 $ 905,500
================================================
</TABLE>
10
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
4. GOODWILL IMPAIRMENT
At December 31, 1995, the Company recognized a goodwill impairment charge of
approximately $3.6 million, with no associated tax benefit, related to the 1994
acquisition of its Ohio Division. The Ohio Division was purchased to be the
Company's entry into the workers compensation, pharmacy benefits management
(PBM) line of business. During the three months ended December 31, 1995, the
contracts attributed to the Ohio Division generated minimal revenue due in part
to the nonexclusive nature of the contracts. In addition, the inability of the
Ohio Division to convert existing relationships with prospective clients into
new PBM contracts or to secure new prospective clients has contributed to
significant operating losses and negative cash flows relative to the Ohio
Division. Based on the continuing poor financial results and the failure to
obtain new contracts, the Company believes that the PBM business acquired with
the Ohio Division will not generate positive cash flows in the foreseeable
future and the strategy to implement this line of business within the Ohio
Division, will no longer be a priority of the Company. Therefore, the Company
wrote-off the unamortized carrying value of the goodwill of approximately $3.6
million on December 31, 1995.
5. NOTES PAYABLE
The Company has entered into various notes payable bearing interest at rates
ranging from 6% to 10% and expiring at various dates through June 1998. The
outstanding balances as of September 30, 1994 and 1995, and December 31, 1995
are $36,120, $31,121 and $26,077, respectively. The carrying value of the
Company's notes payable approximates fair market value.
At December 31, 1995, annual payments on notes payable are as follows:
1996 $18,257
1997 5,950
1998 1,870
=======
$26,077
=======
6. LINE OF CREDIT
In May 1995, the Company entered into a line-of-credit agreement which permits
borrowings up to $750,000. The line of credit is due upon demand and is secured
by substantially all of the assets of the Company. Interest is payable monthly
at prime plus .25% (9.00% and 8.75% at September 30, 1995 and December 31, 1995,
respectively) with a .25% fee on the unused portion of the line. Approximately
$35,000 and $122,000 is outstanding at September 30, 1995 and December 31, 1995,
respectively.
11
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
7. INCOME TAXES
The components of the provision (benefit) for income taxes are as follows:
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
1994 1995 1994 1995
-------------------------------------------------------------
<S> <C> <C> <C> <C>
Current:
Federal $336,039 $121,867 $ 22,293 $ -
State 58,429 21,044 3,816 -
-------------------------------------------------------------
394,468 142,911 26,109 -
Deferred - - (37,413) (39,425)
=============================================================
Total $394,468 $142,911 $(11,304) $(39,425)
=============================================================
</TABLE>
Deferred income taxes are included in other assets on the balance sheet, and
reflect the net tax effects of temporary differences between the carrying amount
of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. Significant components of the Company's net deferred
income taxes are as follows:
SEPTEMBER 30 DECEMBER 31,
1994 1995 1995
----------------------------
Deferred tax assets:
Net operating loss carryforwards $ - $ - $14,271
Change in allowance for
uncollectible accounts - - 25,154
------------------------
$ - $ - $39,425
========================
SFAS No. 109 requires a valuation allowance to reduce the deferred tax assets
reported if, based on the weight of the evidence, it is more likely than not
that some portion or all of the deferred tax assets will not be realized. After
consideration of all the evidence, both positive and negative, management has
determined that no valuation allowance is necessary at December 31, 1995. At
December 31, 1995, the Company has available net operating loss carryforwards of
$37,926, which expire in the year 2010.
12
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
7. INCOME TAXES (CONTINUED)
The differences between the provision for income taxes and the amount which
results from applying the federal and state statutory tax rates to income before
income taxes are as follows:
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31
1994 1995 1994 1995
--------------------------------------------------------------
<S> <C> <C> <C> <C>
Income tax expense (benefit) at
statutory rate $337,253 $ 58,992 $(28,739) $(1,290,553)
State income tax expense (benefit), net
39,677 6,940 (1,090) (3,803)
Interest income not taxable (8,091) - - -
Goodwill amortization notdeductible
for tax purposes 25,010 75,031 16,783 16,783
Goodwill impairment charge not
deductible for tax purposes - - - 1,236,363
Other 619 1,948 1,742 1,785
==============================================================
$394,468 $142,911 $(11,304) $ (39,425)
==============================================================
</TABLE>
8. LEASE COMMITMENTS
The Company has various operating leases, primarily relating to branch offices
and warehouse facilities. The leases have various renewal options and often
require the Company to make additional payments for maintenance costs. The
commitment on the primary branch office is under a five-year lease expiring
December 31, 1996 and subject to escalation clauses as defined in the lease
agreement. Total rent expense for the years ended September 30, 1994 and 1995
and for the three months ended December 31, 1994 and 1995 amounted to $80,477,
$94,144, $27,253 and $27,683, respectively.
Approximate future minimum annual rentals under noncancelable operating leases
with initial or remaining terms in excess of one year are:
1996 $108,897
1997 30,903
1998 27,782
1999 16,005
5,935
--------
$189,522
========
13
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
9. CAPITAL LEASES
The Company leases certain equipment under long-term capital leases. Most of the
Company's leases are for a period of three years. Future obligations are as
follows:
Year ending December 31,
1996 $ 69,712
1997 37,390
1998 17,306
--------
124,408
Less interest (21,100)
--------
$103,308
========
10. PROFIT SHARING PLAN
In 1993, the Company established a profit sharing savings plan (the Plan) that
qualifies as a cash or deferred arrangement under Section 401(k) of the Internal
Revenue Code. Under the Plan, participating employees may defer up to 20% of
their pre-tax salary before reduction, but not more than approximately $9,240
per plan year. The Company may make matching or other contributions to the Plan
There have been no Company contributions to the Plan for the fiscal years ended
September 30, 1994 and 1995 and during the three months ended December 31, 1994
and 1995.
11. STOCK OPTION PLAN
In October 1994, the Company adopted a stock option plan (the Option Plan). The
Option Plan provides for the granting of both incentive stock options and
nonqualified stock options for the purchase of up to 200,000 shares of the
Company's common stock. Under the Option Plan, incentive stock options were
granted during 1995 to purchase 19,100 shares of the Company's common stock for
a period of eight years from October 1996 at an exercise price of $10 per share
There were no nonqualified options granted as of December 31, 1995. There were
no options exercised during the year.
In May 1996, the Company (subsequent to the Acquisition) adopted a stock option
plan (the 1996 Plan). The 1996 Plan provides for the granting of both incentive
stock options and nonqualified stock options for the purchase of up to 900,000
shares of the Company's common stock. Stock options granted under the 1996 Plan
expires after ten years from the date of grant.
14
<PAGE>
CompScript, Inc.
Notes to Financial Statements (continued)
12. SUBSEQUENT EVENTS
In July 1996, the shareholders of the Company increased the authorized common
stock of the Company to 50,000,000 shares of common stock, par value $.0001 per
share.
15
ARTICLES OF AMENDMENT
TO
ARTICLES OF INCORPORATION
OF
CAPITAL BRANDS, INC.
Pursuant to the provisions of ss.607.10025 of the Florida Business
Corporation Act, the undersigned corporation adopts the following Articles of
Amendment to its Articles of Incorporation.
1. The name of the corporation is CAPITAL BRANDS, INC. (the
"Corporation"), Charter #P94000048261, filed on June 28, 1994.
2. The following Amendments to the Articles of Incorporation were
adopted by all of the directors of the Corporation by resolution on May 28,
1996, in the manner prescribed by the Florida Business Corporation Act.
Shareholder consent of the following amendments to the Articles of Incorporation
was approved on July 3, 1996 in the manner prescribed by the Florida Business
Corporation Act.
(A) Article II of the Corporation's Articles of Incorporation
is stated to read in its entirety as follows:
"ARTICLE II
The name of the Corporation shall be: COMPSCRIPT, INC."
(B) The first paragraph of Article III of the Corporation's
Articles of Incorporation shall be and hereby is amended and restated to read
in its entirety as follows:
"ARTICLE III
The aggregate number of shares of all classes of capital stock that
this Corporation shall have authority to issue is fifty-one million
(51,000,000), consisting of (i) fifty million (50,000,000) shares of common
stock, par value $0.0001 per share (the "Common Stock"), and (ii) one million
(1,000,000) shares of preferred stock, par value $0.0001 per share (the
"Preferred Stock")."
3. This Certificate of Amendment shall be effective as of the close of
business on the 5th day of July, 1996, Miami, Florida time, on the date of
filing.
<PAGE>
IN WITNESS WHEREOF, the undersigned, being the Chief Executive Officer
of the Corporation, has executed these Articles of Amendment to the Articles of
Incorporation of Capital Brands, Inc. as of the 3rd day of July, 1996.
CAPITAL BRANDS, INC.,
a Florida corporation
By: /s/ Brian Kahan
-----------------------------
Brian A. Kahan,
Chief Executive Officer
- 2 -
<PAGE>
CERTIFICATE OF AMENDMENT
TO
ARTICLES OF INCORPORATION
OF
CAPITAL BRANDS, INC.
Pursuant to the provisions of ss.607.10025 of the Florida Business
Corporation Act, the undersigned corporation adopts the following Certificate of
Amendment to its Articles of Incorporation:
1. The name of the corporation is CAPITAL BRANDS, Inc. (the
"Corporation"), Charter #P94000048261, filed on June 28, 1994.
2. The following Amendments to the Articles of Incorporation were
adopted by all of the directors of the Corporation by unanimous written consent
effective as of March 14, 1996, in the manner prescribed by the Florida Business
Corporation Act. Shareholder consent of the following amendments to the Articles
of Incorporation was not required pursuant to ss.607.10025 of the Florida
Business Corporation Act:
(A) The first paragraph of Article III of the Corporation's
Articles of Incorporation shall be and hereby is amended and restated to read
in its entirety as follows:
"ARTICLE III
The aggregate number of shares of all classes of
capital stock that this Corporation shall have authority to issue is
thirteen million five hundred thousand (13,500,000), consisting of (i)
twelve million five hundred thousand (12,500,000) shares of common
stock, par value $0.0008 per share (the "Common Stock"), and (ii) one
million (1,000,000) shares of preferred stock, par value $0.0001 per
share (the "Preferred Stock")."
(B) As a new section to Article III of the Corporation's
Articles of Incorporation, Section D is stated to read in its entirety as
follows:
"D. SHARE RECLASSIFICATION
On the date of filing of these Articles of Amendment
with the Secretary of State of the State of Florida, every eight (8)
issued and outstanding shares of the Corporation's previously authorized
common stock, par value $0.0001 per share (the "Old Common Stock") shall
thereby and thereupon be reclassified and converted into one (1) validly
issued, fully paid and nonassessable share of Common Stock (the "New
Common Stock"). Each certificate that theretofore represented shares of
Old Common Stock shall thereafter represent the number of shares of New
Common Stock into which the shares of Old Common Stock represented by
such certificate were reclassified and converted hereby; provided,
however, that each person holding of record a stock certificate or
certificates that represented shares of Old Common Stock shall receive,
upon surrender of such certificate or certificates, a new certificate or
certificates evidencing and representing the number of shares of New
Common Stock to which such person is entitled, except that no fractional
shares resulting from the combination shall be issued, any such
fractional share to be converted to the right of the holder thereof to
receive one share of New Common Stock."
3. The herein amendment to the Articles of Incorporation of the
Corporation does not adversely affect the rights or preferences of the holders
of outstanding shares of any class or series and does not result in the
percentage of authorized shares that remain unissued after the combination
exceeding the percentage of authorized shares that were unissued before the
combination.
4. This Certificate of Amendment shall be effective as of 7:00 a.m.,
Miami, Florida, time, on the date of filing.
<PAGE>
IN WITNESS WHEREOF, the undersigned, being the President and Director of
the Corporation, has executed these Articles of Amendment to the Articles of
Incorporation of Capital Brand, Inc. as of the 24th day of April, 1996.
CAPITAL BRANDS, INC.,
a Florida Corporation
BY: /S/ Mitchell Rubinson
------------------------------
Mitchell Rubinson, President and Director
- 2 -
AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this
"Agreement") is effective as of August 19, 1996 (the "Effective Date"), between
COMPSCRIPT, INC., a Florida corporation (the "Company"), whose principal place
of business is 1225 Broken Sound Parkway, N.W., Suite A, Boca Raton, Florida
33487, and BRIAN A. KAHAN, an individual (the "Employee"), whose address is
__________________________________________.
WHEREAS, the Company is a Florida corporation engaged in providing
consulting, pharmaceutical and accounting services to nursing home and assisted
living residents; and
WHEREAS, the Company presently employs the Employee and desires to
continue to employ the Employee and the Employee desires to continue in the
employ of the Company; and
WHEREAS, the Company has established a valuable reputation and goodwill
in its business, with expertise in all aspects of providing consulting,
pharmaceutical and accounting services to nursing home and assisted living
residents (the "Business"); and
WHEREAS, the Employee has created and established, at least in part,
and is in possession of, the manner, methods, trade secrets and other
confidential information pertaining to the Company's Business;
NOW, THEREFORE, in consideration of the mutual agreements herein made,
the Company and the Employee do hereby agree as follows:
1. RECITALS. The above recitals are true, correct, and are herein
incorporated by reference.
2. EMPLOYMENT. The Company hereby employs the Employee, and the
Employee hereby accepts employment, upon the terms and conditions hereinafter
set forth.
3. AUTHORITY AND POWER DURING EMPLOYMENT PERIOD.
a. DUTIES AND RESPONSIBILITIES. During the term of this Agreement,
Employee shall serve as Chief Executive Officer and Chairman of the Board of
Directors of the Company and shall have general executive and operating
supervision over the property, business and affairs of the Company, its
subsidiaries and divisions, subject to the guidelines and direction of the board
of directors of the Company. It is further the intention of the parties that at
all times during the "Term," as hereinafter defined, of this
<PAGE>
Agreement, the Employee shall serve as a member of the board of directors of the
Company and shall be elected and serve through the Term of the Agreement as
chairman of the board of directors. In the event Employee shall at any time not
be on the board of directors of the Company and serving as chairman of such
board, it shall be presumed (if Employee so elects) that the Employee has been
terminated other than for cause and Employee shall have all of the rights
specified in Section 6.h. of this Agreement just as if the Employee had been
terminated "Without Cause."
b. TIME DEVOTED. Throughout the term of the Agreement, the Employee
shall devote substantially all of the Employee's business time and attention to
the business and affairs of the Company consistent with the Employee's senior
executive position with the Company, except for reasonable vacations and except
for illness or incapacity, but nothing in the Agreement shall preclude the
Employee from engaging in personal business and/or serving as a member of the
board of directors of other related companies, charitable and community affairs,
provided that such activities do not interfere with the regular performance of
the Employee's duties and responsibilities under this Agreement.
4. TERM. The Term of employment hereunder will commence on the
Effective Date as set forth above and be for five (5) years from the Effective
Date provided that the Employee shall be entitled to three one-year extensions
to be exercisable by written notice given by Employee to the Company at least
forty-five (45) days before the expiration of the Term or a Renewal Term, as the
case may be, unless terminated pursuant to Section 6 of this Agreement.
5. COMPENSATION AND BENEFITS.
a. SALARY. The Employee shall be paid a base salary (the "Base
Salary"), payable bi-weekly, at an annual rate of no less than Three Hundred
Thousand Dollars ($300,000) for the first year, with annual incremental
increases of the greater of: (i) the percentage increase in the Consumer Price
Index, all items, as published by the United States Department of Labor, since
the Effective Time (in the case of the first annual increase) or since the most
recent anniversary of the Effective Time (in the case of all subsequent annual
increases), or (ii) six percent (6%) of the previous year's base salary.
b. BONUS COMPENSATION.
i. OPTIONS. Employee shall be granted 160,000 options to purchase
CompScript, Inc. Common Stock at an exercise price of $5.13. Such options shall
vest immediately and expire ten (10) years from the date of this agreement.
ii. PERFORMANCE-BASED BONUS. Employee shall be entitled to a
performance based bonus equal to 10 percent (10%) of net pre-tax profits for
each year. The performance-based bonus shall be payable annually.
2
<PAGE>
c. EMPLOYEE BENEFITS. The Employee shall be entitled to participate
in all benefit programs of the Company currently existing or hereafter made
available to executives and/or other salaried employees, including, but not
limited to, pension and other retirement plans, group life insurance,
hospitalization, surgical and major medical coverage, sick leave, salary
continuation, vacation and holidays, cellular telephone and all related costs
and expenses, long-term disability, and other fringe benefits.
d. VACATION. During each fiscal year of the Company, the Employee
shall be entitled to reasonable time and to utilize such vacation as the
Employee shall determine; provided however, that the Employee shall evidence
reasonable judgment with regard to appropriate vacation scheduling.
Notwithstanding the foregoing, employee shall be entitled to four (4) weeks
vacation per year.
e. BUSINESS EXPENSE REIMBURSEMENT. During the Term and any Renewal
Term of employment, the Employee shall be entitled to receive proper
reimbursement for all reasonable, out-of-pocket expenses incurred by the
Employee (in accordance with the policies and procedures established by the
Company for its senior executive officers) in performing services hereunder,
provided the Employee properly accounts therefor.
f. AUTOMOBILE EXPENSES. The Company shall provide the Employee with
an automobile of the Employee's choice. The Company shall also be responsible
for all expenses in connection with such automobile including, but not limited
to, maintenance, insurance and gas.
g. MEMBERSHIPS, DUES. The Company shall provide to the Employee a
membership in a social, charitable or religious organization or club, which
membership shall be either in the name of the Employee or in the name of the
Company, as determined by the Employee
h. CHARITABLE CONTRIBUTIONS. The Company shall pay or reimburse the
Employee for charitable donations or contributions made, which amount and which
charities shall be determined in the sole discretion of the Employee, provided,
however, that such donations or contributions shall not exceed $25,000 in any
fiscal year.
i. LIFE INSURANCE. The Company shall pay or reimburse Employee for
premiums and other charges associated with such life insurance policies as
Employee and the Company shall mutually agree.
6. CONSEQUENCES OF TERMINATION OF EMPLOYMENT.
a. DEATH. In the event of the death of the Employee during the Term
or any Renewal Term of the Agreement, salary shall be paid to the Employee's
designated beneficiary, or, in the absence of such designation, to the estate or
other legal representative of the Employee for a period of one (1) year from and
after the date
3
<PAGE>
of death. The Company shall also be obligated to pay to the Employee's estate or
heirs, as the case may be, such amount of Bonus based upon (i) the formula set
forth in Section 5(b) of this Agreement for the fiscal year in which the death
of the Employee occurred, (ii) divided by twelve (12); and (iii) then multiplied
by the number of months or any portions thereof the Employee was employed by the
Company just prior to the Employee's death. Except as set forth herein, other
death benefits will be determined in accordance with the terms of the Company's
benefit programs and plans.
b. DISABILITY.
i. In the event of the Employee's disability, as hereinafter
defined, the Employee shall be entitled to compensation in accordance with
the Company's disability compensation practice for senior executives,
including any separate arrangement or policy covering the Employee, but in
all events the Employee shall continue to receive the Employee's salary
for a period, at the annual rate in effect immediately prior to the
commencement of disability, of not less than 180 days from the date on
which the disability has deemed to occur as hereinafter provided below.
Any amounts provided for in this Section 6(b) shall be offset by other
long-term disability benefits provided to the Employee by the Company.
ii. "Disability," for the purposes of this Agreement, shall be
deemed to have occurred in the event (A) the Employee is unable by reason
of sickness or accident, to perform the Employee's duties under this
Agreement for an aggregate of 180 days in any twelve-month period or (B)
the Employee has a guardian of the person or estate appointed by a court
of competent jurisdiction. Termination due to disability shall be deemed
to have occurred upon the first day of the month following the
determination of disability as defined in the preceding sentence.
Anything herein to the contrary notwithstanding, if, following a
termination of employment hereunder due to disability as provided in the
preceding paragraph, the Employee becomes reemployed, whether as an
Employee or a consultant to the Company, any salary, annual incentive
payments or other benefits earned by the Employee from such employment
shall offset any salary continuation due to the Employee hereunder
commencing with the date of re-employment.
c. TERMINATION BY THE COMPANY FOR CAUSE.
i. Nothing herein shall prevent the Company from terminating
Employment for "Cause," as hereinafter defined. The Employee shall
continue to receive salary only for the period ending with the date of
such termination as provided in this Section 6(c). Any rights and benefits
the Employee may have in
4
<PAGE>
respect of any other compensation shall be determined in accordance with
the terms of such other compensation arrangements or such plans or
programs.
ii. "Cause" shall mean and include those actions or events
specified below in subsections (A) through (E) to the extent the same
occur, or the events constituting the same take place, subsequent to the
date of execution of this Agreement: (A) Committing or participating in an
injurious act of fraud, gross neglect or embezzlement against the Company;
(B) committing or participating in any other injurious act or omission
wantonly, willfully, recklessly or in a manner which was grossly negligent
against the Company, monetarily or otherwise; (C) engaging in a criminal
enterprise involving moral turpitude; (D) conviction of an act or acts
constituting a felony under the laws of the United States or any state
thereof; or (E) any assignment of this Agreement by the Employee in
violation of Section 14 of this Agreement. Anything herein to the contrary
notwithstanding, the employment of Employee shall not be terminable by the
Company for Cause if the grounds for such termination includes, but is not
limited to: (i) the result of bad judgment or poor economic results on the
part of the Employee, (ii) any act or omission believed by Employee in
good faith to have been in or not opposed to the interests of the Company,
or (iii) any act or omission in respect of which a determination could
properly be made that Employee met the applicable standard of conduct
described for indemnification or reimbursement or payment of expenses
under the Articles of Incorporation or Bylaws of the Company or the laws
of the State of Florida or the directors' and officers' liability
insurance of the Company, in each case as in effect at the time of such
act or omission.
iii. Notwithstanding anything else contained in this Agreement,
this Agreement will not be deemed to have been terminated for Cause unless
and until there shall have been delivered to the Employee a notice of
termination stating that the Employee committed one of the types of
conduct set forth in this Section 6(c) contained in this Agreement and
specifying the particulars thereof and the Employee shall be given a
thirty (30) day period to cure such conduct, if possible.
d. TERMINATION BY THE COMPANY OTHER THAN FOR CAUSE.
i. The foregoing notwithstanding, the Company may terminate the
Employee's employment for whatever reason it deems appropriate provided,
however, that in the event such termination is not based on cause, as
provided in Section 6(c) above, the Company may terminate this Agreement
upon giving three (3) months' prior written notice. During such three (3)
month period, the Employee shall continue to perform the Employee's duties
pursuant to this Agreement, and the Company shall continue to compensate
the Employee in accordance with this Agreement. The Employee will receive,
at the Employee's option either (A) a lump sum equal to the "Compensation
and Benefits," as
5
<PAGE>
hereinafter defined, for the remaining balance of the Term of this
Agreement, at the then current rate, reduced to present value, as set
forth in Section 280G of the Internal Revenue Code or (B) for the
remaining balance of the Term or any Renewal Term of this Agreement from
and after the date of any such termination and the Company shall on the
last day of each calendar month pay to the Employee such "Compensation and
Benefits," which shall be an amount equal to (Y) one hundred percent
(100%) of the Employee's compensation and benefits set forth in Section 5,
which shall specifically include the Base Salary and Bonus, which Bonus
shall be payable on a pro-rata basis for the year in which the Employee'
employment was terminated other than for cause (the "Compensation and
Benefits"), on the date of any such termination, divided by (Z) twelve
(12); provided however that if (A) there is a decrease in the Employee's
Compensation and Benefits, which specifically include the Employee's then
Base Salary and Bonus, for any reason other than the targets set forth in
Section 5(b) are not met, and (B) the Employee is terminated without
cause, the Compensation and Benefits shall be as existed immediate prior
to such a decrease. The Employee will be entitled to continued
Compensation and Benefits coverage and credits as provided in Section 5 or
to reimbursement for the cost of providing the Employee with comparable
benefit coverage during the term in which the Employee is receiving
payments from the Company after termination pursuant to Section 6(d). Such
benefit coverage will not be offset by comparable coverage provided to the
Employee in connection with subsequent employment.
ii. In the event that the Employee's employment with the Company
is terminated pursuant to this Section 6(d), Section 6(f) or Section 6(g),
Section 7(a) of this Agreement and all references thereto shall be
inapplicable as to the Employee and the Company.
iii. The foregoing notwithstanding, the Employee's employment may
not be terminated by the Company for any reason other than pursuant to
Section 6(a), Section 6(b) and/or Section 6(c) during the first three (3)
years of this Agreement.
e. VOLUNTARY TERMINATION. In the event the Employee terminates the
Employee's employment on the Employee's own volition (except as provided in
Section 6(f) and/or Section 6(g)) prior to the expiration of the Term or during
any Renewal Term of this Agreement, including any renewals thereof, such
termination shall constitute a voluntary termination and in such event the
Employee shall be limited to the same rights and benefits as provided in
connection with a termination for Cause as provided in Section 6(c).
f. CONSTRUCTIVE TERMINATION OF EMPLOYMENT. If the Employee so
elects, a termination by the Company without Cause under Section 6(d) shall be
deemed to have occurred upon the occurrence of one or more of the following
events without the EXPRESS written consent of the Employee:
6
<PAGE>
i. a significant change in the nature or scope of the
authorities, powers, functions, duties or responsibilities attached to
Employee's position as described in Section 3; or
ii. five percent (5%) reduction in the Employee's base salary or
any change in the method of calculating Employee's Bonus Compensation hereunder
which would be detrimental to Employee in any respect; or
iii. a material breach of the Agreement by the Company;
or
iv. a material reduction of the Employee's benefits under any
employee benefit plan, program or arrangement (for Employee individually or as
part of a group) of the Company as then in effect or as in effect on the
Effective Date of the Agreement, which reduction shall not be effectuated for
similarly situated employees of the Company; or
v. failure by a successor company to assume the obligations under
the Agreement.
vi. a change in the Executive principal office to a location
outside the Broward and Palm Beach County, Florida area.
Anything herein to the contrary notwithstanding, the Employee shall give written
notice to the Board of Directors of the Company that the Employee believes an
event has occurred which would result in a Constructive Termination of the
Employee's employment under this Section 6(f), which written notice shall
specify the particular act or acts, on the basis of which the Employee intends
to so terminate the Employee's employment, and the Company shall then be given
the opportunity, within fifteen (15) days of its receipt of such notice to cure
said event, provided, however, there shall be no time period permitted to cure a
second or subsequent occurrence under this Section 6(f) (whether such second
occurrence be of the same or a different event specified in subsections (i)
through (v) above).
g. TERMINATION FOLLOWING A CHANGE OF CONTROL.
i. In the event that a "Change in Control" or an "Attempted
Change in Control" as hereinafter defined, of the Company shall occur at
any time during the Term hereof, the Employee shall have the right to
terminate the Employee's employment under this Agreement upon thirty (30)
days written notice given at any time within one year after the occurrence
of such event, and such termination of the Employee's employment with the
Company pursuant to this Section 6(g)(i), then, in any such event, such
termination shall be deemed to be a Termination by the Company Other than
for Cause and the Employee shall be
7
<PAGE>
entitled to such Compensation and Benefits as set forth in Subsection 6(d)
of this Agreement.
ii. For purposes of this Agreement, a "Change in Control" of the
Company shall mean a change in control (A) as set forth in Section 280G of
the Internal Revenue Code or (B) of a nature that would be required to be
reported in response to Item 1 of the current report on Form 8K, as in
effect on the date hereof, pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 (the "Exchange Act"); provided that,
without limitation, such a change in control shall be deemed to have
occurred at such time as:
(A) any "person", other than the Employee, (as such term is
used in Section 13(d) and 14(d) of the Exchange Act) is or becomes
the "beneficial owner" (as defined in Rule 13d-3 under the Exchange
Act), directly or indirectly, of securities of the Company
representing fifty percent (50%) or more of the combined voting
power of the Company's outstanding securities then having the right
to vote at elections of directors; or,
(B) the individuals who at the commencement date of the
Agreement constitute the Board of Directors cease for any reason to
constitute a majority thereof unless the election, or nomination for
election, of each new director was approved by a vote of at least
two thirds of the directors then in office who were directors at the
commencement of the Agreement; or
(C) there is a failure to elect four or more (or such number
of directors as would constitute a majority of the Board of
Directors) candidates nominated by management of the Company to the
Board of Directors; or
(D) the business of the Company for which the Employee's
services are principally performed is disposed of by the Company
pursuant to a partial or complete liquidation of the Company, a sale
of assets (including stock of a subsidiary of the Company) or
otherwise.
Anything herein to the contrary notwithstanding, this Section 6(g)(ii) will not
apply where the Employee gives the Employee's explicit written waiver stating
that for the purposes of this Section 6(g)(ii) a Change in Control shall not be
deemed to have occurred. The Employee's participation in any negotiations or
other matters in relation to a Change in Control shall in no way constitute such
a waiver which can only be given by an explicit written waiver as provided in
the preceding sentence.
An "Attempted Change in Control" shall be deemed to have occurred if
any substantial attempt, accompanied by significant work efforts and
expenditures of money, is made to accomplish a Change in Control, as described
in subparagraphs (A), (B), (C)
8
<PAGE>
or (D) above whether or not such attempt is made with the approval of a majority
of the then current members of the Board of Directors.
iii. In the event that, within twelve (12) months of any Change in
Control of the Company or any Attempted Change in Control of the Company,
the Company terminates the employment of the Employee under this
Agreement, for any reason other than for Cause as defined in Section 6(c),
or the Employee's employment is constructively terminated as defined in
Section 6(g)(iv), then, in any such event, such termination shall be
deemed to be a Termination by the Company Other than for Cause and the
Employee shall be entitled to such Compensation and Benefits as set forth
in Subsection 6(d) of this Agreement.
iv. For purposes of this Section 6(g), the Employee's employment
shall be deemed constructively terminated in the event one or more of the
following events occurs without the express written consent of the
Employee:
(A) Significant change in the nature or scope of the
authorities, powers, functions, duties or responsibilities attached
to Employee's position as described in Section 3; or
(B) A five percent (5%) reduction in the Employee's salary
below the salary in effect immediately prior to such reduction or a
reduction in the target bonus participation under Section 5(d) as a
percentage of salary; or
(C) Material breach of the Agreement by the Company; or
(D) Material reduction of the Employee's benefits under any
employee benefit plan, program or arrangement (for Employee
individually or as part of a group) of the Company as then in effect
or as in effect on the effective date or the Agreement, which
reduction shall not be effectuated for similarly situated employees
of the Company; or
(E) Failure by a successor company to assume the obligations
under the Agreement; or
(F) Change in the Employee's principal office to a location
outside the Palm Beach-Broward County, Florida area.
v. Anything in this Section 6(g) to the contrary notwithstanding, in
no event will any action or non-action by the Employee at any time prior
to the first anniversary date of the applicable Change in Control or
Attempted Change in Control (including any action or non-action prior to
the effective date of this Agreement) be deemed consent to any of the
events described in this Section 6(g).
9
<PAGE>
vi. Anything herein to the contrary notwithstanding, in the event
the circumstances giving rise to an Attempted Change in Control are
included in those circumstances giving rise to an actual Change in Control
the twelve (12) month period under this Section 6 will be deemed to have
recommenced on the date the actual Change in Control occurred.
7. COVENANT NOT TO COMPETE AND NON-DISCLOSURE OF INFORMATION.
a. COVENANT NOT TO COMPETE. Except as set forth in Section 6(d)(ii)
of this Agreement, the Employee acknowledges and recognizes the highly
competitive nature of the Company's business and the goodwill, continued
patronage, and specifically the names and addresses of the Company's Clients (as
hereinafter defined) constitute a substantial asset of the Company having been
acquired through considerable time, money and effort. Accordingly, in
consideration of the execution of this Agreement, the Employee agrees to the
following:
i. That during the Restricted Period (as hereinafter defined) and
within the Restricted Area (as hereinafter defined), the Employee will
not, individually or in conjunction with others, directly or indirectly,
engage in any Business Activities (as hereinafter defined), whether as an
officer, director, proprietor, employer, partner, independent contractor,
investor (other than as a holder solely as an investment of less than 1%
of the outstanding capital stock of a publicly traded corporation),
consultant, advisor, agent or otherwise.
ii. That during the Restricted Period and within the Restricted
Area, the Employee will not, directly or indirectly, compete with the
Company by soliciting, inducing or influencing any of the Company's
clients which have a business relationship with the Company at the time
during the Restricted Period to discontinue or reduce the extent of such
relationship with the Company.
iii. That during the Restricted Period and within the Restricted
Area, the Employee will not (A) directly or indirectly recruit, solicit or
otherwise influence any employee or agent of the Company to discontinue
such employment or agency relationship with the Company, or (B) employ or
seek to employ, or cause or permit any business which competes directly or
indirectly with the Business Activities of the Company (the "Competitive
Business") to employ or seek to employ for any Competitive Business any
person who is then ( or was at any time within six (6) months prior to the
date Employee or the Competitive Business employs or seeks to employ such
person) employed by the Company.
iv. That during the Restricted Period the Employee will not
interfere with, or disrupt or attempt to disrupt any past, present or
prospective relationship, contractual or otherwise, between the Company
and any customer, employee or agent of the Company.
10
<PAGE>
b. NON-DISCLOSURE OF INFORMATION. The Employee acknowledges that the
Company's trade secrets, private or secret processes, methods and ideas, as they
exist from time to time, customer lists and information concerning the Company's
products, services, training methods, development, technical information,
marketing activities and procedures, credit and financial data concerning the
Company and/or the Company's Clients, and (the "Proprietary Information") are
valuable, special and unique assets of the Company, access to and knowledge of
which are essential to the performance of the Employee hereunder. In light of
the highly competitive nature of the industry in which the Company's business is
conducted, the Employee agrees that all Proprietary Information, heretofore or
in the future obtained by the Employee as a result of the Employee's association
with the Company shall be considered confidential.
In recognition of this fact, the Employee agrees that the Employee,
during the Restricted Period, will not use or disclose any of such Proprietary
Information for the Employee's own purposes or for the benefit of any person or
other entity or organization (except the Company) under any circumstances unless
such Proprietary Information has been publicly disclosed generally or, unless
upon written advice of legal counsel reasonably satisfactory to the Company, the
Employee is legally required to disclose such Proprietary Information. Documents
(as hereinafter defined) prepared by the Employee or that come into the
Employee's possession during the Employee's association with the Company are and
remain the property of the Company, and when this Agreement terminates, such
Documents shall be returned to the Company at the Company's principal place of
business, as provided in the Notice provision (Section 10) of this Agreement.
c. DOCUMENTS. "Documents" shall mean all original written, recorded,
or graphic matters whatsoever, and any and all copies thereof, including, but
not limited to: papers; books; records; tangible things; correspondence;
communications; telex messages; memoranda; work-papers; reports; affidavits;
statements; summaries; analyses; evaluations; client records and information;
agreements; agendas; advertisements; instructions; charges; manuals; brochures;
publications; directories; industry lists; schedules; price lists; client lists;
statistical records; training manuals; computer printouts; books of account,
records and invoices reflecting business operations; all things similar to any
of the foregoing however denominated. In all cases where originals are not
available, the term "Documents" shall also mean identical copies of original
documents or non-identical copies thereof.
d. COMPANY'S CLIENTS. The "Company's Clients" shall be deemed to be
any persons, partnerships, corporations, professional associations or other
organizations for whom the Company has performed Business Activities.
e. RESTRICTIVE PERIOD. The "Restrictive Period" shall be deemed to
be during the Term or Renewal Term of this Agreement and for a period of twelve
(12) months following termination of this Agreement).
11
<PAGE>
f. RESTRICTED AREA. The Restricted Area shall be deemed to mean any
county of any state in which the Company is providing service at the time of
termination.
g. BUSINESS ACTIVITIES. "Business Activities" shall be deemed to
include any business activities concerning consulting, pharmaceutical and
accounting services to nursing homes and assisted living residents provided by
the Company and any additional activities which the Company or any of its
affiliates may engage in during the term of this Agreement.
h. COVENANTS AS ESSENTIAL ELEMENTS OF THIS AGREEMENT. It is
understood by and between the parties hereto that the foregoing covenants
contained in Sections 7(a) and (b) are essential elements of this Agreement, and
that but for the agreement by the Employee to comply with such covenants, the
Company would not have agreed to enter into this Agreement. Such covenants by
the Employee shall be construed to be agreements independent of any other
provisions of this Agreement. The existence of any other claim or cause of
action, whether predicated on any other provision in this Agreement, or
otherwise, as a result of the relationship between the parties shall not
constitute a defense to the enforcement of such covenants against the Employee.
i. SURVIVAL AFTER TERMINATION OF AGREEMENT. Notwithstanding anything
to the contrary contained in this Agreement, the covenants in Sections 7(a) and
(b) shall survive the termination of this Agreement and the Employee's
employment with the Company.
j. REMEDIES.
i. The Employee acknowledges and agrees that the Company's remedy
at law for a breach or threatened breach of any of the provisions of
Section 7(a) or (b) herein would be inadequate and the breach shall be per
se deemed as causing irreparable harm to the Company. In recognition of
this fact, in the event of a breach by the Employee of any of the
provisions of Section 7(a) or (b), the Employee agrees that, in addition
to any remedy at law available to the Company, including, but not limited
to monetary damages, all rights of the Employee to payment or otherwise
under this Agreement and all amounts then or thereafter due to the
Employee from the Company under this Agreement may be terminated and the
Company, without posting any bond, shall be entitled to obtain, and the
Employee agrees not to oppose the Company's request for equitable relief
in the form of specific performance, temporary restraining order,
temporary or permanent injunction or any other equitable remedy which may
then be available to the Company.
ii. The Employee acknowledges that the granting of a temporary
injunction, temporary restraining order or permanent injunction merely
prohibiting the use of Proprietary Information would not be an adequate
remedy upon breach
12
<PAGE>
or threatened breach of Section 7(a) or (b) and consequently agrees, upon
proof of any such breach, to the granting of injunctive relief
prohibiting any form of competition with the Company. Nothing herein
contained shall be construed as prohibiting the Company from pursuing any
other remedies available to it for such breach or threatened breach.
8. INDEMNIFICATION. The Employee shall continue to be covered by the
Articles of Incorporation and/or the Bylaws of the Company with respect to
matters occurring on or prior to the date of termination of the Employee's
employment with the Company, subject to all the provisions of Florida and
Federal law and the Articles of Incorporation and Bylaws of the Company then in
effect. Such reasonable expenses, including attorneys' fees, that may be covered
by the Articles of Incorporation and/or Bylaws of the Company shall be paid by
the Company on a current basis in accordance with such provision, the Company's
Articles of Incorporation and Florida law. To the extent that any such payments
by the Company pursuant to the Company's Articles of Incorporation and/or Bylaws
may be subject to repayment by the Employee pursuant to the provisions of the
Company's Articles of Incorporation or Bylaws, or pursuant to Florida or Federal
law, such repayment shall be due and payable by the Employee to the Company
within twelve (12) months after the termination of all proceedings, if any,
which relate to such repayment and to the Company's affairs for the period prior
to the date of termination of the Employee's employment with the Company and as
to which Employee has been covered by such applicable provisions.
9. WITHHOLDING. Anything to the contrary notwithstanding, all payments
required to be made by the Company hereunder to the Employee or the Employee's
estate or beneficiaries shall be subject to the withholding of such amounts, if
any, relating to tax and other payroll deductions as the Company may reasonably
determine it should withhold pursuant to any applicable law or regulation. In
lieu of withholding such amounts, the Company may accept other arrangements
pursuant to which it is satisfied that such tax and other payroll obligations
will be satisfied in a manner complying with applicable law or regulation.
10. NOTICES. Any notice required or permitted to be given under the terms
of this Agreement shall be sufficient if in writing and if sent postage prepaid
by registered or certified mail, return receipt requested; by overnight
delivery; by courier; or by confirmed telecopy, in the case of the Employee to
the Employee's last place of business or residence as shown on the records of
the Company, or in the case of the Company to its principal office as set forth
in the first paragraph of this Agreement, or at such other place as it may
designate.
11. WAIVER. Unless agreed in writing, the failure of either party, at any
time, to require performance by the other of any provisions hereunder shall not
affect its right thereafter to enforce the same, nor shall a waiver by either
party of any breach of any provision hereof be taken or held to be a waiver of
any other preceding or succeeding breach of any term or provision of this
Agreement. No extension of time for the
13
<PAGE>
performance of any obligation or act shall be deemed to be an extension of time
for the performance of any other obligation or act hereunder.
12. COMPLETENESS AND MODIFICATION. This Agreement constitutes the entire
understanding between the parties hereto superseding all prior and
contemporaneous agreements or understandings among the parties hereto concerning
the Employment Agreement. This Agreement may be amended, modified, superseded or
canceled, and any of the terms, covenants, representations, warranties or
conditions hereof may be waived, only by a written instrument executed by the
parties or, in the case of a waiver, by the party to be charged.
13. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which shall
constitute but one agreement.
14. BINDING EFFECT/ASSIGNMENT. This Agreement shall be binding upon the
parties hereto, their heirs, legal representatives, successors and assigns. This
Agreement shall not be assignable by the Employee but shall be assignable by the
Company in connection with the sale, transfer or other disposition of its
business or to any of the Company's affiliates controlled by or under common
control with the Company.
15. GOVERNING LAW. This Agreement shall become valid when executed and
accepted by Company. The parties agree that it shall be deemed made and entered
into in the State of Florida and shall be governed and construed under and in
accordance with the laws of the State of Florida. Anything in this Agreement to
the contrary notwithstanding, the Employee shall conduct the Employee's business
in a lawful manner and faithfully comply with applicable laws or regulations of
the state, city or other political subdivision in which the Employee is located.
16. FURTHER ASSURANCES. All parties hereto shall execute and deliver such
other instruments and do such other acts as may be necessary to carry out the
intent and purposes of this Agreement.
17. HEADINGS. The headings of the sections are for convenience only and
shall not control or affect the meaning or construction or limit the scope or
intent of any of the provisions of this Agreement.
18. SURVIVAL. Any termination of this Agreement shall not, however, affect
the ongoing provisions of this Agreement which shall survive such termination in
accordance with their terms.
19. SEVERABILITY. The invalidity or unenforceability, in whole or in part,
of any covenant, promise or undertaking, or any section, subsection, paragraph,
sentence,
14
<PAGE>
lause, phrase or word or of any provision of this Agreement shall not affect
the validity or enforceability of the remaining portions thereof.
20. ENFORCEMENT. Should it become necessary for any party to institute
legal action to enforce the terms and conditions of this Agreement, the
successful party will be awarded reasonable attorneys' fees at all trial and
appellate levels, expenses and costs.
21. VENUE. Company and Employee acknowledge and agree that the U.S.
District for the Southern District of Florida, or if such court lacks
jurisdiction, the 15th Judicial Circuit (or its successor) in and for Palm Beach
County, Florida, shall be the venue and exclusive proper forum in which to
adjudicate any case or controversy arising either, directly or indirectly, under
or in connection with this Agreement and the parties further agree that, in the
event of litigation arising out of or in connection with this Agreement in these
courts, they will not contest or challenge the jurisdiction or venue of these
courts.
22. CONSTRUCTION. This Agreement shall be construed within the fair
meaning of each of its terms and not against the party drafting the document.
THE EMPLOYEE ACKNOWLEDGES THAT THE EMPLOYEE HAS READ ALL OF THE TERMS OF THIS
AGREEMENT, UNDERSTANDS THE AGREEMENT, AND AGREES TO ABIDE BY ITS TERMS AND
CONDITIONS.
IN WITNESS WHEREOF, the parties have executed this Agreement as of date set
forth in the first paragraph of this Agreement.
Witness: THE COMPANY:
COMPSCRIPT, INC.
By: /S/ GARY SPLAIN
- ----------------------------- --------------------------
Witness: THE EMPLOYEE:
/S/ BRIAN A. KAHAN
- ----------------------------- ------------------------------
Brian A. Kahan
15
LIST OF SUBSIDIARIES
1. CompScript - Boca, Inc.
2. Securx, Inc.
3. CompScript - Mobile, Inc.
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 333-05627) pertaining to the Consulting Agreements of Capital
Brands, Inc. of our report dated August 23, 1996, with respect to the financial
statements of CompScript, Inc. included in the Transition Report (Form 10-KSB)
for the three months ended December 31, 1995.
Ernst & Young, LLP
West Palm Beach, Florida
October 7, 1996
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-START> OCT-01-1995
<PERIOD-END> DEC-31-1995
<CASH> 263,033
<SECURITIES> 0
<RECEIVABLES> 1,795,253
<ALLOWANCES> (66,845)
<INVENTORY> 483,019
<CURRENT-ASSETS> 2,532,924
<PP&E> 1,434,883
<DEPRECIATION> (529,383)
<TOTAL-ASSETS> 3,721,190
<CURRENT-LIABILITIES> 731,647
<BONDS> 0
0
0
<COMMON> 5,499,153
<OTHER-SE> (2,562,787)
<TOTAL-LIABILITY-AND-EQUITY> 3,721,190
<SALES> 2,903,723
<TOTAL-REVENUES> 2,903,723
<CGS> 1,461,453
<TOTAL-COSTS> 1,461,453
<OTHER-EXPENSES> 1,594,092
<LOSS-PROVISION> 3,636,362
<INTEREST-EXPENSE> 11,282
<INCOME-PRETAX> (3,795,744)
<INCOME-TAX> 39,425
<INCOME-CONTINUING> (3,756,319)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,756,319)
<EPS-PRIMARY> (1.84)
<EPS-DILUTED> (1.84)
</TABLE>
